BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103-107. [PMID: 9756471 DOI: 10.1126/science.282.5386.103] [Cited by in Crossref: 1495] [Cited by in F6Publishing: 1259] [Article Influence: 65.0] [Reference Citation Analysis]
Number Citing Articles
1 Pawlotsky JM. Is hepatitis virus resistance to antiviral drugs a threat? Gastroenterology 2012;142:1369-72. [PMID: 22537445 DOI: 10.1053/j.gastro.2011.12.060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5. [PMID: 19152711 DOI: 10.1186/1471-230X-9-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
3 Ahmed F, Jacobson IM. Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterol Clin North Am 2004;33:513-26, viii. [PMID: 15324941 DOI: 10.1016/j.gtc.2004.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
4 Vargas-de-león C. Global properties for virus dynamics model with mitotic transmission and intracellular delay. Journal of Mathematical Analysis and Applications 2011;381:884-90. [DOI: 10.1016/j.jmaa.2011.04.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Best K, Guedj J, Madelain V, de Lamballerie X, Lim SY, Osuna CE, Whitney JB, Perelson AS. Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proc Natl Acad Sci U S A 2017;114:8847-52. [PMID: 28765371 DOI: 10.1073/pnas.1704011114] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 15.8] [Reference Citation Analysis]
6 Godkin A, Openshaw P, Thomas HC. Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. J Viral Hepat 2005;12:604-8. [PMID: 16255761 DOI: 10.1111/j.1365-2893.2005.00627.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
7 Balasubramanian A, Groopman JE, Ganju RK. Underlying pathophysiology of HCV infection in HIV-positive drug users. J Addict Dis 2008;27:75-82. [PMID: 18681194 DOI: 10.1300/J069v27n02_09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Meredith LW, Farquhar MJ, Tarr AW, McKeating JA. Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. Hepatology 2014;60:1891-901. [PMID: 25066844 DOI: 10.1002/hep.27333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
9 Kim AY, Timm J. Resistance mechanisms in HCV: from evolution to intervention. Expert Rev Anti Infect Ther 2008;6:463-78. [PMID: 18662114 DOI: 10.1586/14787210.6.4.463] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zeng Q, Nair AG, Rosenblum SB, Huang H, Lesburg CA, Jiang Y, Selyutin O, Chan T, Bennett F, Chen KX, Venkatraman S, Sannigrahi M, Velazquez F, Duca JS, Gavalas S, Huang Y, Pu H, Wang L, Pinto P, Vibulbhan B, Agrawal S, Ferrari E, Jiang C, Li C, Hesk D, Gesell J, Sorota S, Shih N, Njoroge FG, Kozlowski JA. Discovery of an irreversible HCV NS5B polymerase inhibitor. Bioorganic & Medicinal Chemistry Letters 2013;23:6585-7. [DOI: 10.1016/j.bmcl.2013.10.060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Burke KP, Cox AL. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res. 2010;47:216-227. [PMID: 20066508 DOI: 10.1007/s12026-009-8152-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
12 Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J. Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol. 2012;86:11956-11966. [PMID: 22855498 DOI: 10.1128/jvi.01079-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
13 Soriano V, Martin-carbonero L, Maida I, Garcia-samaniego J, Nuñez M. New paradigms in the management of HIV and hepatitis C virus coinfection: . Current Opinion in Infectious Diseases 2005;18:550-60. [DOI: 10.1097/01.qco.0000191509.56104.ec] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
14 Gregori J, Salicrú M, Domingo E, Sanchez A, Esteban JI, Rodríguez-Frías F, Quer J. Inference with viral quasispecies diversity indices: clonal and NGS approaches. Bioinformatics 2014;30:1104-11. [PMID: 24389655 DOI: 10.1093/bioinformatics/btt768] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
15 Blower S, Ganem D. Mathematicians turn their attention to hepatitis C. Nat Med 1998;4:1233-4. [DOI: 10.1038/3210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Dahari H, Perelson AS. Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World J Gastroenterol 2007;13:3020-1. [PMID: 17589958 DOI: 10.3748/wjg.v13.i21.3020] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
17 Guedj J, Dahari H, Uprichard SL, Perelson AS. The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert Rev Gastroenterol Hepatol 2013;7:397-9. [PMID: 23899277 DOI: 10.1586/17474124.2013.811050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
18 Lechner F, Sullivan J, Spiegel H, Nixon DF, Ferrari B, Davis A, Borkowsky B, Pollack H, Barnes E, Dusheiko G, Klenerman P. Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philos Trans R Soc Lond B Biol Sci 2000;355:1085-92. [PMID: 11186310 DOI: 10.1098/rstb.2000.0646] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
19 Pinky L, Gonzalez-Parra G, Dobrovolny HM. Effect of stochasticity on coinfection dynamics of respiratory viruses. BMC Bioinformatics 2019;20:191. [PMID: 30991939 DOI: 10.1186/s12859-019-2793-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Luciani F, Alizon S. The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus. PLoS Comput Biol 2009;5:e1000565. [PMID: 19911046 DOI: 10.1371/journal.pcbi.1000565] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
21 Weisberg IS, Jacobson IM. Telaprevir: hope on the horizon, getting closer. Clin Liver Dis 2009;13:441-52. [PMID: 19628160 DOI: 10.1016/j.cld.2009.05.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
22 Lau DT, Negash A, Chen J, Crochet N, Sinha M, Zhang Y, Guedj J, Holder S, Saito T, Lemon SM. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology. 2013;144:402-413.e12. [PMID: 23123437 DOI: 10.1053/j.gastro.2012.10.044] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
23 Iwami S, Koizumi Y, Ikeda H, Kakizoe Y. Quantification of viral infection dynamics in animal experiments. Front Microbiol 2013;4:264. [PMID: 24058361 DOI: 10.3389/fmicb.2013.00264] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ferenci P. Treatment of chronic hepatitis C—how much interferon is enough? Nat Rev Gastroenterol Hepatol 2010;7:191-3. [DOI: 10.1038/nrgastro.2010.40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL, Neely RD. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology. 2010;139:1774-1783, 1783.e1-e6. [PMID: 20682323 DOI: 10.1053/j.gastro.2010.07.047] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
26 Dahari H, Shudo E, Ribeiro RM, Perelson AS. Mathematical modeling of HCV infection and treatment. Methods Mol Biol. 2009;510:439-453. [PMID: 19009281 DOI: 10.1007/978-1-59745-394-3_33] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
27 Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, Boom R. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 2002;40:788-93. [PMID: 11880394 DOI: 10.1128/JCM.40.3.788-793.2002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
28 Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M Jr, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis 2009;200:866-76. [PMID: 19673650 DOI: 10.1086/605475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Gretch D. Mechanism of interferon resistance in hepatitis C. The Lancet 2001;358:1662-4. [DOI: 10.1016/s0140-6736(01)06728-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Andriulli A, Dalgard O, Bjøro K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Digestive and Liver Disease 2006;38:741-8. [DOI: 10.1016/j.dld.2006.06.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
31 Chang M, Williams O, Mittler J, Quintanilla A, Carithers RL Jr, Perkins J, Corey L, Gretch DR. Dynamics of hepatitis C virus replication in human liver. Am J Pathol 2003;163:433-44. [PMID: 12875965 DOI: 10.1016/S0002-9440(10)63673-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
32 Dahari H, Guedj J, Perelson AS, Layden TJ. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. Curr Hepat Rep 2011;10:214-27. [PMID: 22180724 DOI: 10.1007/s11901-011-0101-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
33 Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology. 2004;39:1709-1720. [PMID: 15185313 DOI: 10.1002/hep.20239] [Cited by in Crossref: 111] [Cited by in F6Publishing: 103] [Article Influence: 6.5] [Reference Citation Analysis]
34 Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87-S99. [PMID: 25920094 DOI: 10.1016/j.jhep.2015.02.006] [Cited by in Crossref: 217] [Cited by in F6Publishing: 195] [Article Influence: 43.4] [Reference Citation Analysis]
35 Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013;444:329-336. [PMID: 23876458 DOI: 10.1016/j.virol.2013.06.029] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
36 Perelson AS, Layden TJ. Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 2007;132:2050-2. [PMID: 17484896 DOI: 10.1053/j.gastro.2007.03.077] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
37 Cacoub P, Benhamou Y. Place des interférons dans le traitement des infections par les virusde l'hépatite B et de l'hépatite C. La Revue de Médecine Interne 2002;23:459S-74S. [DOI: 10.1016/s0248-8663(02)00660-4] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
38 Reinharz V, Churkin A, Lewkiewicz S, Dahari H, Barash D. A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics. Bull Math Biol 2019;81:3675-721. [PMID: 31338739 DOI: 10.1007/s11538-019-00644-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Adalja AA, Watson M, Toner ES, Cicero A, Inglesby TV. Characteristics of Microbes Most Likely to Cause Pandemics and Global Catastrophes. Curr Top Microbiol Immunol 2019;424:1-20. [PMID: 31463536 DOI: 10.1007/82_2019_176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
40 Gonzalez HJ, Ho SB, Gross JB, Peine C, McKee D, Smith T; Midwest Hepatitis Study Group. Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C. Dig Dis Sci 2002;47:784-92. [PMID: 11991610 DOI: 10.1023/a:1014792017251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294-9299. [PMID: 15939869 DOI: 10.1073/pnas.0503596102.] [Reference Citation Analysis]
42 Simon PF, de La Vega MA, Paradis É, Mendoza E, Coombs KM, Kobasa D, Beauchemin CAA. Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses. Sci Rep 2016;6:24154. [PMID: 27080193 DOI: 10.1038/srep24154] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
43 Ishikawa T, Abe S, Kojima Y, Sano T, Iwanaga A, Seki KI, Honma T, Yoshida T, Yamazaki M, Sakai T, Tasaki K, Suzuki Y. Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin. Exp Ther Med 2015;9:1646-50. [PMID: 26136872 DOI: 10.3892/etm.2015.2340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
44 To J, Torres J. Beyond Channel Activity: Protein-Protein Interactions Involving Viroporins. Subcell Biochem 2018;88:329-77. [PMID: 29900504 DOI: 10.1007/978-981-10-8456-0_15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Larrat S, Kulkarni O, Claude JB, Beugnot R, Blum MG, Fusillier K, Lupo J, Tremeaux P, Plages A, Marlu A, Duborjal H, Signori-Schmuck A, Francois O, Zarski JP, Morand P, Leroy V. Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients. J Clin Microbiol 2015;53:389-97. [PMID: 25411182 DOI: 10.1128/JCM.02547-14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Herrmann E, Zeuzem S. Hepatitis C viral kinetic models. Cell Death Differ 2003;10:S7-8. [DOI: 10.1038/sj.cdd.4401118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
47 Zitzmann C, Schmid B, Ruggieri A, Perelson AS, Binder M, Bartenschlager R, Kaderali L. A Coupled Mathematical Model of the Intracellular Replication of Dengue Virus and the Host Cell Immune Response to Infection. Front Microbiol 2020;11:725. [PMID: 32411105 DOI: 10.3389/fmicb.2020.00725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
48 Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol. 2003;39:421-427. [PMID: 12927929 DOI: 10.1016/S0168-8278(03)00287-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Toapanta-Yanchapaxi L, Páez-Zayas VM, Cuevas-Castillejos JE, Lizárraga-Gómez E, García-Juárez I. What do we know about detectable viremia at the end of hepatitis C virus treatment and the subsequent sustained virologic response? Rev Gastroenterol Mex (Engl Ed) 2019;84:526-8. [PMID: 31167745 DOI: 10.1016/j.rgmx.2019.01.005] [Reference Citation Analysis]
50 Kim K, Kim S, Sasase N, Taniguchi M, Harada S, Kinoshita K, Kim S, Akimoto Y, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Motojima M, Kinoshita M, Hirai M, Ohzu M, Hirooka T, Nabeshima S, Ishii F, Tanaka K, Hotta H. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C. J Clin Pharm Ther 2006;31:441-6. [DOI: 10.1111/j.1365-2710.2006.00761.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
51 Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol. 2000;32:98-112. [PMID: 10728798 DOI: 10.1016/s0168-8278(00)80419-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 15] [Article Influence: 5.4] [Reference Citation Analysis]
52 Han B, Parhy B, Lu J, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H. In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir. J Clin Microbiol 2019;57:e01844-18. [PMID: 30728196 DOI: 10.1128/JCM.01844-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
53 Kinoshita C, Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Satoh K, Sutoh S, Abe H, Tsubota A, Aizawa Y. Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles. World J Gastroenterol 2016;22:6716-25. [PMID: 27547014 DOI: 10.3748/wjg.v22.i29.6716] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Bull RA, Luciani F, McElroy K, Gaudieri S, Pham ST, Chopra A, Cameron B, Maher L, Dore GJ, White PA. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog. 2011;7:e1002243. [PMID: 21912520 DOI: 10.1371/journal.ppat.1002243] [Cited by in Crossref: 170] [Cited by in F6Publishing: 159] [Article Influence: 17.0] [Reference Citation Analysis]
55 Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver. 2002;22:121-126. [PMID: 12028405 DOI: 10.1034/j.1600-0676.2002.01579.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
56 Manzin A, Candela M, Solforosi L, Gabrielli A, Clementi M. Dynamics of hepatitis C viremia after plasma exchange. Journal of Hepatology 1999;31:389-93. [DOI: 10.1016/s0168-8278(99)80027-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Glass L. Dynamical disease: Challenges for nonlinear dynamics and medicine. Chaos 2015;25:097603. [DOI: 10.1063/1.4915529] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
58 Gonçalves A, Lemenuel-Diot A, Cosson V, Jin Y, Feng S, Bo Q, Guedj J. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383-92. [PMID: 33074571 DOI: 10.1111/jvh.13425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
59 Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol. 2005;42:491-498. [PMID: 15763335 DOI: 10.1016/j.jhep.2004.12.017] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
60 Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LGC. Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study. Arq Gastroenterol 2006;43:275-9. [DOI: 10.1590/s0004-28032006000400006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Dang YX, Li XZ, Martcheva M. Competitive exclusion in a multi-strain immuno-epidemiological influenza model with environmental transmission. J Biol Dyn 2016;10:416-56. [PMID: 27608293 DOI: 10.1080/17513758.2016.1217355] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
62 Manzin A, Solforosi L, Debiaggi M, Zara F, Tanzi E, Romanò L, Zanetti AR, Clementi M. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol. 2000;74:4327-4334. [PMID: 10756048 DOI: 10.1128/jvi.74.9.4327-4334.2000] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
63 Hsu C, Hsu S, Chen H, Liu C, Jeng J, Liu C, Chen P, Chen D, Kao J. Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. Hepatol Int 2013;7:171-9. [DOI: 10.1007/s12072-012-9390-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
64 Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010;84:5067-77. [PMID: 20200239 DOI: 10.1128/JVI.02265-09] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
65 Hu K, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18. [DOI: 10.1046/j.1365-2893.2001.00253.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]
66 Abbas Z, Hamid S, Tabassum S. High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naive to therapy. J Gastroenterol Hepatol 2002;17:577-81. [DOI: 10.1046/j.1440-1746.2002.02711.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Guedj J, Neumann AU. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 2010;267:330-40. [PMID: 20831874 DOI: 10.1016/j.jtbi.2010.08.036] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
68 Chen KX, Nair L, Vibulbhan B, Yang W, Arasappan A, Bogen SL, Venkatraman S, Bennett F, Pan W, Blackman ML, Padilla AI, Prongay A, Cheng KC, Tong X, Shih NY, Njoroge FG. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease. J Med Chem 2009;52:1370-9. [PMID: 19196021 DOI: 10.1021/jm801238q] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
69 Berger M, Kaup M, Blanchard V. Protein glycosylation and its impact on biotechnology. Adv Biochem Eng Biotechnol 2012;127:165-85. [PMID: 21975953 DOI: 10.1007/10_2011_101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
70 McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol. 2006;44:411-421. [PMID: 16364491 DOI: 10.1016/j.jhep.2005.12.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
71 Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites 2021;11:273. [PMID: 33925362 DOI: 10.3390/metabo11050273] [Reference Citation Analysis]
72 Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D’Amato M, Pohl RT, Weiss G, Ashkenazi YJ, Tichler T, Goldin E. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int. 2015;35:289-294. [PMID: 25251042 DOI: 10.1111/liv.12692] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
73 Cao W, Sun B, Feitelson MA, Wu T, Tur-Kaspa R, Fan Q. Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int J Cancer 2009;124:2886-92. [PMID: 19253371 DOI: 10.1002/ijc.24265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
74 Chevaliez S. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance. Clin Res Hepatol Gastroenterol 2011;35 Suppl 2:S46-51. [PMID: 22248694 DOI: 10.1016/S2210-7401(11)70007-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, Zeuzem S. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat 2005;12:307-14. [PMID: 15850472 DOI: 10.1111/j.1365-2893.2005.00594.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
76 Quer J, Murillo P, Martell M, Gómez J, Esteban JI, Esteban R, Guardia J. Subtype mutations in the envelope 2 region including phosphorylation homology domain of Hepatitis C virus do not predict effectiveness of antiviral therapy: Subtype mutations in PePHD of HCV. Journal of Viral Hepatitis 2004;11:45-54. [DOI: 10.1046/j.1352-0504.2003.00465.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
77 Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol. 2008;82:1665-1678. [PMID: 18077728 DOI: 10.1128/jvi.02113-07] [Cited by in Crossref: 204] [Cited by in F6Publishing: 133] [Article Influence: 14.6] [Reference Citation Analysis]
78 Davis BC, Thorpe IF. Molecular simulations illuminate the role of regulatory components of the RNA polymerase from the hepatitis C virus in influencing protein structure and dynamics. Biochemistry 2013;52:4541-52. [PMID: 23738897 DOI: 10.1021/bi400251g] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
79 Fornai C, Maggi F, Favilli F, Vatteroni ML, Pistello M, Marchi S, Ciccorossi P, Antonelli G, Bendinelli M. Rapid changes in hepatitis C virus quasispecies produced by a single dose of IFN-alpha in chronically infected patients. J Interferon Cytokine Res. 2001;21:417-422. [PMID: 11440639 DOI: 10.1089/107999001750277899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
80 Zhang X, Zhang N, Chen G, Turpoff A, Ren H, Takasugi J, Morrill C, Zhu J, Li C, Lennox W, Paget S, Liu Y, Almstead N, George Njoroge F, Gu Z, Komatsu T, Clausen V, Espiritu C, Graci J, Colacino J, Lahser F, Risher N, Weetall M, Nomeir A, Karp GM. Discovery of novel HCV inhibitors: Synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. Bioorganic & Medicinal Chemistry Letters 2013;23:3947-53. [DOI: 10.1016/j.bmcl.2013.04.049] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
81 Maasoumy B, Vermehren J. Diagnostics in hepatitis C: The end of response-guided therapy? J Hepatol 2016;65:S67-81. [PMID: 27641989 DOI: 10.1016/j.jhep.2016.07.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
82 Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207 Suppl 1:S33-S39. [PMID: 23390303 DOI: 10.1093/infdis/jis761] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
83 de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA. Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2011;56:95-9. [PMID: 21157362 DOI: 10.1097/QAI.0b013e3182020596] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
84 Verbinnen T, Van Marck H, Vandenbroucke I, Vijgen L, Claes M, Lin TI, Simmen K, Neyts J, Fanning G, Lenz O. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol. 2010;84:11124-11133. [PMID: 20739521 DOI: 10.1128/jvi.01217-10] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
85 Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology. 2003;38:509-517. [PMID: 12883496 DOI: 10.1053/jhep.2003.50344] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
86 Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 2013;62:1340-6. [PMID: 23135762 DOI: 10.1136/gutjnl-2012-302553] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
87 Kraus S, Kleines M, Albers J, Blohm L, Piechotta G, Püttmann C, Barth S, Nähring J, Nebling E. Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform. Biosensors and Bioelectronics 2011;26:1895-901. [DOI: 10.1016/j.bios.2010.03.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
88 Wasik S, Jackowiak P, Figlerowicz M, Blazewicz J. Multi-agent model of hepatitis C virus infection. Artif Intell Med 2014;60:123-31. [PMID: 24309221 DOI: 10.1016/j.artmed.2013.11.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
89 Smits M, Zoldan K, Ishaque N, Gu Z, Jechow K, Wieland D, Conrad C, Eils R, Fauvelle C, Baumert TF, Emmerich F, Bengsch B, Neumann-Haefelin C, Hofmann M, Thimme R, Boettler T. Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination. J Clin Invest. 2020;130:998-1009. [PMID: 31697649 DOI: 10.1172/jci129642] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
90 Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J Gastroenterol. 2007;13:4808-4817. [PMID: 17828811 DOI: 10.3748/wjg.v13.i36.4808] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
91 Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H. Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. J Virol 2015;89:6551-61. [PMID: 25833046 DOI: 10.1128/JVI.00016-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
92 Canini L, Carrat F. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 2011;85:2764-70. [PMID: 21191031 DOI: 10.1128/JVI.01318-10] [Cited by in Crossref: 71] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
93 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
94 Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL, Walker CM. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 2001;15:883-895. [PMID: 11754811 DOI: 10.1016/s1074-7613(01)00245-x] [Cited by in Crossref: 305] [Cited by in F6Publishing: 143] [Article Influence: 16.1] [Reference Citation Analysis]
95 Reiser M, Buggisch P, Grossmann J, Koop K, Wursthorn K, Schmiegel W. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2003;15:1299-304. [DOI: 10.1097/00042737-200312000-00008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Dalgard O, Bjoro K, Ring-larsen H, Verbaan H. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. European Journal of Gastroenterology & Hepatology 2010;22:552-6. [DOI: 10.1097/meg.0b013e328335b29e] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
97 Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol. 2008;128:133-147. [PMID: 18514579 DOI: 10.1016/j.clim.2008.03.525] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
98 Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, Salvadori M, Como G, Ponticelli C, Graziani G. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis. 2003;42:143-150. [PMID: 12830466 DOI: 10.1016/s0272-6386(03)00417-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
99 Thys K, Verhasselt P, Reumers J, Verbist BM, Maes B, Aerssens J. Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. J Virol Methods 2015;221:29-38. [PMID: 25917877 DOI: 10.1016/j.jviromet.2015.04.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
100 Begemann F, Jablonowski H. Enhancing the response to interferon-alpha. J Clin Virol. 1999;13:1-7. [PMID: 10405886 DOI: 10.1016/s1386-6532(99)00009-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
101 Fujino T, Nakamuta M, Aoyagi Y, Kohjima M, Satoh T, Fukuda M, Ishibashi H, Yatsuhashi H, Enjoji M. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit 2011;17:CR687-91. [PMID: 22129899 DOI: 10.12659/msm.882127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
102 Bailey J. An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 2. Alternative Replacement Methods. Altern Lab Anim 2010;38:471-94. [DOI: 10.1177/026119291003800602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
103 Zhou Y, Müh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, Brennan DL, Tigges AM, Swenson L, Kwong AD, Lin C. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007;282:22619-28. [PMID: 17556358 DOI: 10.1074/jbc.M610207200] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
104 Clementi M. Quantitative Molecular Analysis of Virus Expression and Replication. J Clin Microbiol 2000;38:2030-6. [DOI: 10.1128/jcm.38.6.2030-2036.2000] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
105 Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7:6716-29. [PMID: 26694454 DOI: 10.3390/v7122968] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
106 Welsch C. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. Drug Discovery Today: Technologies 2014;11:19-25. [DOI: 10.1016/j.ddtec.2013.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
107 Schiffer JT, Wald A, Selke S, Corey L, Magaret A. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 2011;204:554-61. [PMID: 21791657 DOI: 10.1093/infdis/jir314] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
108 Netski DM, Mao Q, Ray SC, Klein RS. Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression. J Acquir Immune Defic Syndr 2008;49:136-41. [PMID: 18769357 DOI: 10.1097/QAI.0b013e3181869a6f] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
109 Pearlman BL. Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. World J Gastroenterol 2008;14:3621-7. [PMID: 18595128 DOI: 10.3748/wjg.14.3621] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
110 López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Castellanos ME, Pardo M, Bartolomé J, Quiroga JA, Carreño V. The role of genomic and antigenomic HCV-RNA strands as predictive factors of response to pegylated interferon plus ribavirin therapy. Aliment Pharmacol Ther 2007;25:1193-201. [PMID: 17451565 DOI: 10.1111/j.1365-2036.2007.03314.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
111 Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol. 1999;31 Suppl 1:61-64. [PMID: 10622562 DOI: 10.1016/s0168-8278(99)80376-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
112 Pfaender S, Brown RJ, Pietschmann T, Steinmann E. Natural reservoirs for homologs of hepatitis C virus. Emerg Microbes Infect 2014;3:e21. [PMID: 26038514 DOI: 10.1038/emi.2014.19] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
113 Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006;35:463-486. [PMID: 16880075 DOI: 10.1016/j.gtc.2006.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
114 Wu R, Geng D, Chi X, Wang X, Gao X, Xu H, Shi Y, Guan Y, Wang Y, Jin J, Ding Y, Niu J. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019;12:2987-3015. [PMID: 31571951 DOI: 10.2147/idr.s218584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
115 Adiwijaya BS, Kieffer TL, Henshaw J, Eisenhauer K, Kimko H, Alam JJ, Kauffman RS, Garg V. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol 2012;8:e1002339. [PMID: 22241977 DOI: 10.1371/journal.pcbi.1002339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
116 Perreault C. The Origin and Role of MHC Class I-Associated Self-Peptides. Development of T Cell Immunity. Elsevier; 2010. pp. 41-60. [DOI: 10.1016/s1877-1173(10)92003-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
117 Rosen HR, Ribeiro RR, Weinberger L, Wolf S, Chung M, Gretch DR, Perelson AS. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol 2002;37:124-30. [PMID: 12076871 DOI: 10.1016/s0168-8278(02)00114-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
118 Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology. 2002;36:1259-1265. [PMID: 12395338 DOI: 10.1053/jhep.2002.36781] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 3.9] [Reference Citation Analysis]
119 Mangia A. Short-duration therapy for hepatitis C: suitable for all? J Viral Hepat 2007;14:221-7. [DOI: 10.1111/j.1365-2893.2006.00817.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
120 Knop V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Neumann K, Sarrazin C, Zeuzem S, Berg T. Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Annals of Hepatology 2013;12:190-8. [DOI: 10.1016/s1665-2681(19)31356-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
121 Bingham RJ, Dykeman EC, Twarock R. RNA Virus Evolution via a Quasispecies-Based Model Reveals a Drug Target with a High Barrier to Resistance. Viruses 2017;9:E347. [PMID: 29149077 DOI: 10.3390/v9110347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
122 Müller V, Marée AF, De Boer RJ. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood. J Virol 2001;75:2597-603. [PMID: 11222682 DOI: 10.1128/JVI.75.6.2597-2603.2001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
123 Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54:1137-1144. [PMID: 21145810 DOI: 10.1016/j.jhep.2010.08.029] [Cited by in Crossref: 177] [Cited by in F6Publishing: 172] [Article Influence: 17.7] [Reference Citation Analysis]
124 McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene. 2011;30:1969-1983. [PMID: 21258404 DOI: 10.1038/onc.2010.594] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 13.6] [Reference Citation Analysis]
125 Heim MH. Innate immunity and HCV. J Hepatol. 2013;58:564-574. [PMID: 23063572 DOI: 10.1016/j.jhep.2012.10.005] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 11.6] [Reference Citation Analysis]
126 Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat. 2003;10:335-342. [PMID: 12969183 DOI: 10.1046/j.1365-2893.2003.00452.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 4.0] [Reference Citation Analysis]
127 Lindh M, Arnholm B, Eilard A, Färkkilä M, Hellstrand K, Lagging M, Langeland N, Mørch K, Nilsson S, Pedersen C. Hepatitis C treatment response kinetics and impact of baseline predictors. J Viral Hepat. 2011;18:400-407. [PMID: 20500548 DOI: 10.1111/j.1365-2893.2010.01323.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
128 Gupta A, Quigg RJ. Glomerular Diseases Associated With Hepatitis B and C. Advances in Chronic Kidney Disease 2015;22:343-51. [DOI: 10.1053/j.ackd.2015.06.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
129 Magalini A, Puoti M, Putzolu V, Quiros-Roldan E, Forleo MA, Rossi S, Zaltron S, Spinetti A, Zanini B, Zonaro A, Solfrini R, Carosi G. Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month. J Clin Lab Anal 2000;14:120-4. [PMID: 10797610 DOI: 10.1002/(sici)1098-2825(2000)14:3<120::aid-jcla6>3.0.co;2-#] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Komarova NL. Viral reproductive strategies: How can lytic viruses be evolutionarily competitive? J Theor Biol 2007;249:766-84. [PMID: 17945261 DOI: 10.1016/j.jtbi.2007.09.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
131 Appleby TC, Perry JK, Murakami E, Barauskas O, Feng J, Cho A, Fox D 3rd, Wetmore DR, McGrath ME, Ray AS, Sofia MJ, Swaminathan S, Edwards TE. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science 2015;347:771-5. [PMID: 25678663 DOI: 10.1126/science.1259210] [Cited by in Crossref: 187] [Cited by in F6Publishing: 156] [Article Influence: 31.2] [Reference Citation Analysis]
132 Perelson AS. Viral kinetics and mathematical models. Am J Med 1999;107:49S-52S. [PMID: 10653457 DOI: 10.1016/s0002-9343(99)00382-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
133 Luik A, Knapp S, Thursz M, Thomas HC, Schlaak JF. Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. J Interferon Cytokine Res 2004;24:585-93. [PMID: 15626155 DOI: 10.1089/jir.2004.24.585] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
134 Neumann AU. Hepatitis B viral kinetics: A dynamic puzzle still to be resolved. Hepatology 2005;42:249-54. [DOI: 10.1002/hep.20831] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
135 DebRoy S, Hiraga N, Imamura M, Hayes CN, Akamatsu S, Canini L, Perelson AS, Pohl RT, Persiani S, Uprichard SL, Tateno C, Dahari H, Chayama K. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J Viral Hepat 2016;23:708-17. [PMID: 27272497 DOI: 10.1111/jvh.12551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
136 de Lédinghen V, Trimoulet P, Winnock M, Bernard P, Bourlière M, Portal I, Rémy A, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P. Daily or three times per week interferon α-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. Journal of Hepatology 2002;36:819-26. [DOI: 10.1016/s0168-8278(02)00071-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
137 Durso-Cain K, Kumberger P, Schälte Y, Fink T, Dahari H, Hasenauer J, Uprichard SL, Graw F. HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics. Viruses 2021;13:1308. [PMID: 34372514 DOI: 10.3390/v13071308] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Focosi D, Farrugia A. The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. Int J Infect Dis 2021;102:244-6. [PMID: 33130197 DOI: 10.1016/j.ijid.2020.10.074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
139 Knodel MM, Reiter S, Targett-Adams P, Grillo A, Herrmann E, Wittum G. 3D Spatially Resolved Models of the Intracellular Dynamics of the Hepatitis C Genome Replication Cycle. Viruses 2017;9:E282. [PMID: 28973992 DOI: 10.3390/v9100282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
140 Cotler SJ, Reddy KR, Mccone J, Wolfe DL, Liu A, Craft TR, Ferris MW, Conrad AJ, Albrecht J, Morrissey M, Ganger DR, Rosenblate H, Blatt LM, Jensen DM, Taylor MW. An Analysis of Acute Changes in Interleukin-6 Levels After Treatment of Hepatitis C with Consensus Interferon. Journal of Interferon & Cytokine Research 2001;21:1011-9. [DOI: 10.1089/107999001317205132] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
141 Matsumori A, Shimada M, Obata T. Leukocytes are the major target of hepatitis C virus infection: Possible mechanism of multiorgan involvement including the heart. CVD Prevention and Control 2010;5:51-8. [DOI: 10.1016/j.cvdpc.2010.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
142 Korolowicz KE, Iyer RP, Czerwinski S, Suresh M, Yang J, Padmanabhan S, Sheri A, Pandey RK, Skell J, Marquis JK, Kallakury BV, Tucker RD, Menne S. Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS One. 2016;11:e0161313. [PMID: 27552102 DOI: 10.1371/journal.pone.0161313] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
143 Israelow B, Mullokandov G, Agudo J, Sourisseau M, Bashir A, Maldonado AY, Dar AC, Brown BD, Evans MJ. Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nat Commun 2014;5:5408. [PMID: 25403145 DOI: 10.1038/ncomms6408] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
144 Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64-71. [PMID: 24583028 DOI: 10.1016/j.antiviral.2014.02.011] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
145 González-Parra G, Dobrovolny HM. A quantitative assessment of dynamical differences of RSV infections in vitro and in vivo. Virology 2018;523:129-39. [PMID: 30144786 DOI: 10.1016/j.virol.2018.07.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
146 Rong L, Guedj J, Dahari H, Coffield DJ, Levi M, Smith P, Perelson AS. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol. 2013;9:e1002959. [PMID: 23516348 DOI: 10.1371/journal.pcbi.1002959] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
147 Smith AM, Adler FR, McAuley JL, Gutenkunst RN, Ribeiro RM, McCullers JA, Perelson AS. Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol 2011;7:e1001081. [PMID: 21379324 DOI: 10.1371/journal.pcbi.1001081] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
148 Brown RJ, Juttla VS, Tarr AW, Finnis R, Irving WL, Hemsley S, Flower DR, Borrow P, Ball JK. Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol. 2005;86:1931-1942. [PMID: 15958671 DOI: 10.1099/vir.0.80957-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
149 Taylor DR, Shi ST, Lai MM. Hepatitis C virus and interferon resistance. Microbes Infect 2000;2:1743-56. [PMID: 11137047 DOI: 10.1016/s1286-4579(00)01329-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
150 Thiébaut R, Guedj J, Jacqmin-Gadda H, Chêne G, Trimoulet P, Neau D, Commenges D. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol 2006;6:38. [PMID: 16879756 DOI: 10.1186/1471-2288-6-38] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
151 Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM. Silymarin for HCV infection. Antivir Ther 2013;18:141-7. [PMID: 23011959 DOI: 10.3851/IMP2402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
152 Welsch C, Shimakami T, Hartmann C, Yang Y, Domingues FS, Lengauer T, Zeuzem S, Lemon SM. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. Gastroenterology 2012;142:654-63. [PMID: 22155364 DOI: 10.1053/j.gastro.2011.11.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
153 Chen KX, Njoroge FG, Vibulbhan B, Prongay A, Pichardo J, Madison V, Buevich A, Chan T. Proline-Based Macrocyclic Inhibitors of the Hepatitis C Virus: Stereoselective Synthesis and Biological Activity. Angew Chem Int Ed 2005;44:7024-8. [DOI: 10.1002/anie.200501553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
154 Dahari H, Sainz B Jr, Perelson AS, Uprichard SL. Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol 2009;83:6383-90. [PMID: 19369346 DOI: 10.1128/JVI.02612-08] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
155 Ganusov VV, Lukacher AE, Byers AM. Persistence of viral infection despite similar killing efficacy of antiviral CD8(+) T cells during acute and chronic phases of infection. Virology 2010;405:193-200. [PMID: 20580390 DOI: 10.1016/j.virol.2010.05.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
156 Rong L, Guedj J, Dahari H, Perelson AS. Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Antivir Ther. 2014;19:469-477. [PMID: 24434478 DOI: 10.3851/imp2725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
157 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
158 Nair LG, Bogen S, Ruan S, Pan W, Pike R, Tong X, Cheng K, Guo Z, Doll RJ, Njoroge FG. Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors. Bioorganic & Medicinal Chemistry Letters 2010;20:1689-92. [DOI: 10.1016/j.bmcl.2010.01.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
159 Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19:17-25. [PMID: 23593605 DOI: 10.3350/cmh.2013.19.1.17] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 10.5] [Reference Citation Analysis]
160 Lalande L, Bourguignon L, Maire P, Goutelle S. Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study. J Theor Biol 2016;399:43-52. [PMID: 27059890 DOI: 10.1016/j.jtbi.2016.03.038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
161 Madelain V, Mentré F, Baize S, Anglaret X, Laouénan C, Oestereich L, Nguyen THT, Malvy D, Piorkowski G, Graw F, Günther S, Raoul H, de Lamballerie X, Guedj J. Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT Pharmacometrics Syst Pharmacol 2020;9:258-71. [PMID: 32198838 DOI: 10.1002/psp4.12510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
162 Chao DL, Davenport MP, Forrest S, Perelson AS. Modelling the impact of antigen kinetics on T‐cell activation and response. Immunol Cell Biol 2004;82:55-61. [DOI: 10.1111/j.1440-1711.2004.01207.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
163 Irshad M. Retracted: Genetic diversity in hepatitis C virus (HCV): A brief review. Rev Med Virol 2008;19. [PMID: 19089864 DOI: 10.1002/rmv.603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
164 Duchesne L, Njouom R, Lissock F, Tamko-Mella GF, Rallier S, Poiteau L, Soulier A, Chevaliez S, Vernet G, Rouveau N, Pawlotsky JM, Girard PM, Lacombe K. HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc 2017;20:21446. [PMID: 28530032 DOI: 10.7448/IAS.20.1.21446] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
165 Ye L, Wang X, Wang S, Luo G, Wang Y, Liang H, Ho W. Centrifugal enhancement of hepatitis C virus infection of human hepatocytes. J Virol Methods 2008;148:161-5. [PMID: 18178263 DOI: 10.1016/j.jviromet.2007.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
166 Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014;60:1902-1910. [PMID: 25098971 DOI: 10.1002/hep.27357] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
167 Bae IH, Kim HS, You Y, Chough C, Choe W, Seon MK, Lee SG, Keum G, Jang SK, Moon Kim B. Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. Eur J Med Chem 2015;101:163-78. [PMID: 26134551 DOI: 10.1016/j.ejmech.2015.06.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
168 Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M, Murata M, Sawayama Y, Hayashi J. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol. 2010;10:38. [PMID: 20398383 DOI: 10.1186/1471-230x-10-38] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
169 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
170 Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2007;45:262-8. [PMID: 17414926 DOI: 10.1097/QAI.0b013e3180559219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
171 Urban T, Charlton MR, Goldstein DB. Introduction to the genetics and biology of interleukin-28B. Hepatology 2012;56:361-6. [PMID: 22511448 DOI: 10.1002/hep.25794] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
172 Scott J, Holte S, Urban T, Burgess C, Coppel E, Wang C, Corey L, McHutchison J, Goldstein D. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J Infect Dis 2011;204:419-25. [PMID: 21742841 DOI: 10.1093/infdis/jir264] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
173 Brown RS. Customizing treatment to patient populations. Nat Rev Gastroenterol Hepatol 2007;4:S3-9. [DOI: 10.1038/ncpgasthep0693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
174 Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001;54:84-8. [PMID: 11215290 DOI: 10.1136/jcp.54.2.84] [Cited by in Crossref: 87] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
175 Hörnfeldt E, Gjertsen H, Weiland O. High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Scandinavian Journal of Infectious Diseases 2009;40:259-65. [DOI: 10.1080/00365540701633020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
176 Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW. Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001;1:14. [PMID: 11801193 DOI: 10.1186/1471-230x-1-14] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
177 Coburn GA, Fisch DN, Moorji SM, de Muys JM, Murga JD, Paul D, Provoncha KP, Rotshteyn Y, Han AQ, Qian D. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. PLoS One. 2012;7:e35351. [PMID: 22545104 DOI: 10.1371/journal.pone.0035351] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
178 Gibbert K, Dietze KK, Zelinskyy G, Lang KS, Barchet W, Kirschning CJ, Dittmer U. Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol 2010;185:6179-89. [PMID: 20943997 DOI: 10.4049/jimmunol.1000858] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
179 Madelain V, Oestereich L, Graw F, Nguyen TH, de Lamballerie X, Mentré F, Günther S, Guedj J. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res 2015;123:70-7. [PMID: 26343011 DOI: 10.1016/j.antiviral.2015.08.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
180 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Reference Citation Analysis]
181 Cotler SJ, Layden JE, Neumann AU, Jensen DM. First phase hepatitis c viral kinetics in previous nonresponders patients. J Viral Hepat 2003;10:43-9. [DOI: 10.1046/j.1365-2893.2003.00401.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
182 Kimura Y, Gushima T, Rawale S, Kaumaya P, Walker CM. Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol. 2005;79:4870-4876. [PMID: 15795272 DOI: 10.1128/jvi.79.8.4870-4876.2005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
183 Graw F, Balagopal A, Kandathil AJ, Ray SC, Thomas DL, Ribeiro RM, Perelson AS. Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Comput Biol 2014;10:e1003934. [PMID: 25393308 DOI: 10.1371/journal.pcbi.1003934] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
184 Itakura J, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Itakura Y, Tamaki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Takahashi Y, Maekawa S, Enomoto N, Izumi N. Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. PLoS One 2015;10:e0138060. [PMID: 26368554 DOI: 10.1371/journal.pone.0138060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
185 Kohno H, Aimitsu S, Kitamoto M, Aisaka Y, Kawakami H, Chayama K. Prolonged Negative HCV-RNA Status Led to a Good Outcome in Chronic Hepatitis C Patients with Genotype 1b and Super-High Viral Load. Intervirology 2006;49:362-9. [DOI: 10.1159/000095156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
186 Dickow J, Francois S, Kaiserling RL, Malyshkina A, Drexler I, Westendorf AM, Lang KS, Santiago ML, Dittmer U, Sutter K. Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8+ T Cell Responses. Front Immunol 2019;10:2255. [PMID: 31608062 DOI: 10.3389/fimmu.2019.02255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
187 Layden TJ, Layden JE, Ribeiro RM, Perelson AS. Mathematical modeling of viral kinetics:. Clinics in Liver Disease 2003;7:163-78. [DOI: 10.1016/s1089-3261(02)00063-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
188 Engler S, Flechtenmacher C, Wiedemann KH, Gugler R, Stremmel W, Kallinowski B. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat. 2004;11:60-68. [PMID: 14738559 DOI: 10.1046/j.1352-0504.2003.00463.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
189 Scotto G, Campanozzi F, D??adduzio A, Grimaldi M, Fazio V. Interferon-?? (IFN??) Daily Dose Versus IFN?? Plus Ribavirin for Treatment-Naive Chronic Hepatitis??? C Patients Infected by Genotype 1b: . BioDrugs 2003;17:281-6. [DOI: 10.2165/00063030-200317040-00007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
190 Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556. [PMID: 11827565 DOI: 10.2165/00003495-200262030-00009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
191 Mihm U, Welker MW, Teuber G, Wedemeyer H, Berg T, Sarrazin C, Böhm S, Alshuth U, Herrmann E, Zeuzem S. Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J Viral Hepat 2014;21:42-52. [PMID: 24329856 DOI: 10.1111/jvh.12124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
192 Samreen B, Khaliq S, Ashfaq UA, Khan M, Afzal N, Shahzad MA, Riaz S, Jahan S. Hepatitis C virus entry: role of host and viral factors. Infect Genet Evol. 2012;12:1699-1709. [PMID: 22878095 DOI: 10.1016/j.meegid.2012.07.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
193 Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA. 2000;97:8039-8044. [PMID: 10859361 DOI: 10.1073/pnas.140123497] [Cited by in Crossref: 149] [Cited by in F6Publishing: 121] [Article Influence: 7.1] [Reference Citation Analysis]
194 Layden JE, Layden TJ. How can mathematics help us understand HCV? Gastroenterology 2001;120:1546-9. [DOI: 10.1053/gast.2001.24401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
195 Talal AH, Chen Y, Zeremski M, Zavala R, Sylvester C, Kuhns M, Brown LS, Markatou M, Cloherty GA. Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders. J Subst Abuse Treat 2017;78:37-42. [PMID: 28554601 DOI: 10.1016/j.jsat.2017.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Dymock BW. Emerging therapies for hepatitis C virus infection. Emerging Drugs 2005;6:13-42. [DOI: 10.1517/14728214.6.1.13] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
197 Akamatsu S, Hayes CN, Ochi H, Uchida T, Kan H, Murakami E, Abe H, Tsuge M, Miki D, Akiyama R, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. Journal of Hepatology 2015;63:554-63. [DOI: 10.1016/j.jhep.2015.03.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
198 Christie JM, Chapel H, Chapman RW, Rosenberg WM. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology. 1999;30:1037-1044. [PMID: 10498657 DOI: 10.1002/hep.510300403] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]
199 Murray JM, Purcell RH, Wieland SF. The half-life of hepatitis B virions. Hepatology. 2006;44:1117-1121. [PMID: 17058221 DOI: 10.1002/hep.21364] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
200 Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem. 2014;57:5057-5071. [PMID: 24749835 DOI: 10.1021/jm500335h] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 10.4] [Reference Citation Analysis]
201 Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467-1475. [PMID: 20951424 DOI: 10.1016/s0140-6736(10)61384-0] [Cited by in Crossref: 252] [Cited by in F6Publishing: 77] [Article Influence: 22.9] [Reference Citation Analysis]
202 Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol. 2010;134:237-250. [PMID: 19910258 DOI: 10.1016/j.clim.2009.10.007] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 8.3] [Reference Citation Analysis]
203 Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU; DITTO-HCV study group. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat 2012;19:488-96. [PMID: 22676361 DOI: 10.1111/j.1365-2893.2011.01569.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
204 Brady DE, Torres DM, An JW, Ward JA, Lawitz E, Harrison SA. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Clin Gastroenterol Hepatol 2010;8:66-71.e1. [PMID: 19747986 DOI: 10.1016/j.cgh.2009.08.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
205 Ribeiro RM, Perelson AS. Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase. J Hepatol 2002;37:277-9. [PMID: 12127436 DOI: 10.1016/s0168-8278(02)00210-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
206 Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat. 2014;21:229-240. [PMID: 24597691 DOI: 10.1111/jvh.12230] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 7.9] [Reference Citation Analysis]
207 Arazi A, Pendergraft WF 3rd, Ribeiro RM, Perelson AS, Hacohen N. Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches. Semin Immunol 2013;25:193-200. [PMID: 23375135 DOI: 10.1016/j.smim.2012.11.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
208 Lutchman G, Hoofnagle JH. Viral kinetics in hepatitis C. Hepatology 2003;37:1257-9. [PMID: 12774002 DOI: 10.1053/jhep.2003.50238] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
209 Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004;20:825-830. [PMID: 15479353 DOI: 10.1111/j.1365-2036.2004.02170.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
210 Maeda N, Watanabe M, Okamoto S, Kanai T, Yamada T, Hata J, Hozumi N, Katsume A, Nuriya H, Sandhu J. Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone. Liver Int. 2004;24:259-267. [PMID: 15189278 DOI: 10.1111/j.1478-3231.2004.0909.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
211 Bíró L, Varga L, Pár A, Nemesánszky E, Csepregi A, Telegdy L, Ibrányi E, Dávid K, Horváth G, Szentgyörgyi L, Nagy I, Dalmi L, Abonyi M, Füst G, Horányi M. Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b. Immunol Lett 2000;72:69-74. [PMID: 10841940 DOI: 10.1016/s0165-2478(00)00183-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
212 Prejean C, Colamonici OR. Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling. Semin Cancer Biol 2000;10:83-92. [PMID: 10936059 DOI: 10.1006/scbi.2000.0311] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
213 Jeffers LJ. Treating hepatitis C in African Americans. Liver Int 2007;27:313-22. [PMID: 17355451 DOI: 10.1111/j.1478-3231.2006.01438.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
214 Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van ‘t Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913-921. [PMID: 19852962 DOI: 10.1053/j.gastro.2009.10.033] [Cited by in Crossref: 125] [Cited by in F6Publishing: 114] [Article Influence: 10.4] [Reference Citation Analysis]
215 Ramirez S, Perez-del-pulgar S, Carrion JA, Coto-llerena M, Mensa L, Dragun J, Garcia-valdecasas JC, Navasa M, Forns X. Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. Journal of General Virology 2010;91:1183-8. [DOI: 10.1099/vir.0.018929-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
216 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
217 Dahari H, Perelson AS. Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology 2007;46:2048-9; author reply 2049-50. [PMID: 17935224 DOI: 10.1002/hep.21798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
218 Debroy S, Kribs-zaleta C, Mubayi A, Cardona-meléndez GM, Medina-rios L, Kang M, Diaz E. Evaluating treatment of hepatitis C for hemolytic anemia management. Mathematical Biosciences 2010;225:141-55. [DOI: 10.1016/j.mbs.2010.02.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
219 Mathy JE, Ma S, Compton T, Lin K. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. 2008;52:3267-3275. [PMID: 18591281 DOI: 10.1128/aac.00498-08] [Cited by in Crossref: 48] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
220 Soriano V, Rodríguez-rosado R, García-samaniego J. Management of chronic hepatitis C in HIV-infected patients: . AIDS 1999;13:539-46. [DOI: 10.1097/00002030-199904010-00002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 3.5] [Reference Citation Analysis]
221 Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004;40:1442-9. [PMID: 15565603 DOI: 10.1002/hep.20487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
222 Handel A, Longini IM Jr, Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. J R Soc Interface 2010;7:35-47. [PMID: 19474085 DOI: 10.1098/rsif.2009.0067] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 8.3] [Reference Citation Analysis]
223 Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007;14:371-86. [PMID: 17501757 DOI: 10.1111/j.1365-2893.2006.00816.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
224 Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother 2011;66:959-63. [PMID: 21406435 DOI: 10.1093/jac/dkr090] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
225 Raghwani J, Rose R, Sheridan I, Lemey P, Suchard MA, Santantonio T, Farci P, Klenerman P, Pybus OG. Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection. PLoS Pathog 2016;12:e1005894. [PMID: 27631086 DOI: 10.1371/journal.ppat.1005894] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
226 Medeiros-Filho JE, de Carvalho Mello IM, Pinho JR, Neumann AU, de Mello Malta F, da Silva LC, Carrilho FJ. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006;12:7271-7. [PMID: 17143940 DOI: 10.3748/wjg.v12.i45.7271] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
227 Lukasiewicz E, Gorfine M, Freedman LS, Pawlotsky J, Schalm SW, Ferrari C, Zeuzem S, Neumann AU; for the DITTO-HCV Study Group. Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. Journal of Viral Hepatitis 2010;17:345-51. [DOI: 10.1111/j.1365-2893.2009.01183.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
228 Koizumi Y, Iwami S. Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs. Theor Biol Med Model 2014;11:41. [PMID: 25252828 DOI: 10.1186/1742-4682-11-41] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
229 Bush CO, Pokrovskii MV, Saito R, Morganelli P, Canales E, Clarke MO, Lazerwith SE, Golde J, Reid BG, Babaoglu K. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother. 2014;58:386-396. [PMID: 24165192 DOI: 10.1128/aac.02083-13] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
230 Albert ML, Decalf J, Pol S. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. J Hepatol 2008;49:1069-78. [PMID: 18929418 DOI: 10.1016/j.jhep.2008.09.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
231 Wodarz D. Mathematical models of immune effector responses to viral infections: Virus control versus the development of pathology. Journal of Computational and Applied Mathematics 2005;184:301-19. [DOI: 10.1016/j.cam.2004.08.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
232 Dreux M, Cosset F. Detection of Neutralizing Antibodies with HCV Pseudoparticles (HCVpp). In: Tang H, editor. Hepatitis C: Methods and Protocols. Totowa: Humana Press; 2009. pp. 427-38. [DOI: 10.1007/978-1-59745-394-3_32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
233 Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, Titerence R, Koh C, Cherepanov V, Heller T. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology. 2011;140:830-839. [PMID: 20854821 DOI: 10.1053/j.gastro.2010.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
234 Vinogradova SV, Zhudenkov KV, Benson N, Van Der Graaf PH, Demin OV, Karelina TA. Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis. J Theor Biol 2015;382:91-8. [PMID: 26163367 DOI: 10.1016/j.jtbi.2015.06.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Brown LV, Gaffney EA, Wagg J, Coles MC. Applications of mechanistic modelling to clinical and experimental immunology: an emerging technology to accelerate immunotherapeutic discovery and development. Clin Exp Immunol 2018;193:284-92. [PMID: 30240512 DOI: 10.1111/cei.13182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
236 Schweitzer CJ, Liang TJ. Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 2013;3:501-7. [PMID: 23835049 DOI: 10.1016/j.coviro.2013.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
237 Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V, Bartenschlager R. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol. 2003;84:1253-1259. [PMID: 12692291 DOI: 10.1099/vir.0.18997-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 3.8] [Reference Citation Analysis]
238 Bain VG. Effect of HCV viral dynamics on treatment design: lessons learned from HIV. Am J Gastroenterol 2001;96:2818-28. [PMID: 11693314 DOI: 10.1111/j.1572-0241.2001.04234.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
239 Bayram M, Koksal AR, Alkim H, Boga S, Ergun M, Ozdogan O, Altinkaya E, Alkim C. First Week HCV RNA Level Under the Pegylated Interferon and Ribavirin Treatment Predicts Sustained Virological Response. Am J Ther 2016;23:e1612-8. [PMID: 25933139 DOI: 10.1097/MJT.0000000000000279] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
240 Thomas H, Török M, Forton D, Taylor-robinson S. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. Journal of Hepatology 1999;31:152-9. [DOI: 10.1016/s0168-8278(99)80393-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
241 Raja R, Baral S, Dixit NM. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. Immunol Rev 2018;285:55-71. [PMID: 30129199 DOI: 10.1111/imr.12689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
242 González-Parra G, Dobrovolny HM. Modeling of fusion inhibitor treatment of RSV in African green monkeys. J Theor Biol 2018;456:62-73. [PMID: 30048719 DOI: 10.1016/j.jtbi.2018.07.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
243 Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis. 2003;7:45-66. [PMID: 12691458 DOI: 10.1016/s1089-3261(02)00065-x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
244 Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 2012;109:9499-504. [PMID: 22623528 DOI: 10.1073/pnas.1202924109] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 12.4] [Reference Citation Analysis]
245 Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005;102:9294-9299. [PMID: 15939869 DOI: 10.1073/pnas.0503596102] [Cited by in Crossref: 1374] [Cited by in F6Publishing: 1312] [Article Influence: 85.9] [Reference Citation Analysis]
246 You Y, Kim HS, Bae IH, Lee SG, Jee MH, Keum G, Jang SK, Kim BM. New potent biaryl sulfate-based hepatitis C virus inhibitors. Eur J Med Chem 2017;125:87-100. [PMID: 27657807 DOI: 10.1016/j.ejmech.2016.09.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
247 Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouso K, Iwasaki Y. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro. Liver Int. 2010;30:1324-1331. [PMID: 20602680 DOI: 10.1111/j.1478-3231.2010.02299.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
248 Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology. 2009;49:1113-1121. [PMID: 19115219 DOI: 10.1002/hep.22754] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
249 Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA. 2013;110:3991-3996. [PMID: 23431163 DOI: 10.1073/pnas.1203110110] [Cited by in Crossref: 231] [Cited by in F6Publishing: 208] [Article Influence: 28.9] [Reference Citation Analysis]
250 Leggewie M, Sreenu VB, Abdelrahman T, Leitch EC, Wilkie GS, Klymenko T, Muir D, Thursz M, Main J, Thomson EC. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS. 2013;27:2485-2488. [PMID: 23770494 DOI: 10.1097/qad.0b013e328363b1f9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
251 Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol. 2001;79:515-536. [PMID: 11903612 DOI: 10.1046/j.1440-1711.2001.01036.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 3.3] [Reference Citation Analysis]
252 Ciupe SM, Vaidya NK, Forde JE. Early events in hepatitis B infection: the role of inoculum dose. Proc Biol Sci 2021;288:20202715. [PMID: 33563115 DOI: 10.1098/rspb.2020.2715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Webb GF, Blaser MJ. Dynamics of bacterial phenotype selection in a colonized host. Proc Natl Acad Sci U S A 2002;99:3135-40. [PMID: 11867714 DOI: 10.1073/pnas.042685799] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
254 Guedj J, Bazzoli C, Neumann AU, Mentré F. Design evaluation and optimization for models of hepatitis C viral dynamics. Stat Med 2011;30:1045-56. [PMID: 21337592 DOI: 10.1002/sim.4191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
255 Obaid MA, Elaiw AM. Stability of Virus Infection Models with Antibodies and Chronically Infected Cells. Abstract and Applied Analysis 2014;2014:1-12. [DOI: 10.1155/2014/650371] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
256 Shu H, Wang L, Watmough J. Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model. J Math Biol 2014;68:477-503. [DOI: 10.1007/s00285-012-0639-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
257 Kim HY, Kwon HD, Jang TS, Lim J, Lee HS. Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy. PLoS One 2012;7:e50377. [PMID: 23209728 DOI: 10.1371/journal.pone.0050377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
258 Iwona BO, Karol P, Kamila CC, Pollak A, Hanna B, Agnieszka P, Andrzej H, Kosińska J, Płoski R, Tomasz L, Marek R. Next-generation sequencing analysis of new genotypes appearing during antiviral treatment of chronic hepatitis C reveals that these are selected from pre-existing minor strains. J Gen Virol 2018;99:1633-42. [PMID: 30394872 DOI: 10.1099/jgv.0.001160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Parczewski M, Janczewska E, Pisula A, Dybowska D, Łojewski W, Witor A, Wawrzynowicz-Syczewska M, Socha Ł, Krygier R, Knysz B, Musialik J, Urbańska A, Scheibe K, Jaroszewicz J. HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland. Infect Genet Evol 2021;93:104949. [PMID: 34087494 DOI: 10.1016/j.meegid.2021.104949] [Reference Citation Analysis]
260 Argentini C, Genovese D, Dettori S, Rapicetta M. HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiol. 2009;4:359-373. [PMID: 19327119 DOI: 10.2217/fmb.09.8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
261 Darling JM, Fried MW. Optimizing treatment regimens in hepatitis C. Clin Liver Dis 2006;10:835-50. [PMID: 17164120 DOI: 10.1016/j.cld.2006.08.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
262 de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. J Clin Virol. 2006;36:60-63. [PMID: 16418013 DOI: 10.1016/j.jcv.2005.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
263 McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;45 Suppl 2:S47-56; discussion S66-7. [PMID: 17704692 DOI: 10.1097/QAI.0b013e318068d190] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
264 Hahn YS. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol. 2003;15:443-449. [PMID: 12900277 DOI: 10.1016/s0952-7915(03)00076-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
265 Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology. 2013;57:2155-2163. [PMID: 23504636 DOI: 10.1002/hep.26386] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
266 Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? Sci Rep 2017;7:10233. [PMID: 28860456 DOI: 10.1038/s41598-017-09776-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
267 Schuchmann M, Kittner JM, Schlaak JF, Klass DM, Eisenbach C, Berg T, Trautwein C, Günther R, Zeuzem S, Gösseringer R, Ehrlich A, Neumann K, Wachtlin D, Sprinzl MF, Zimmermann T, Böcher WO, Galle PR. No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. Dig Liver Dis 2013;45:323-9. [PMID: 23245590 DOI: 10.1016/j.dld.2012.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
268 Bernardin F, Stramer SL, Rehermann B, Page-Shafer K, Cooper S, Bangsberg DR, Hahn J, Tobler L, Busch M, Delwart E. High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology 2007;365:446-56. [PMID: 17493654 DOI: 10.1016/j.virol.2007.04.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
269 Imran M, Manzoor S, Parvaiz F. Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol 2014;27:404-11. [PMID: 25198668 DOI: 10.1089/vim.2014.0044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
270 Dahari H, Cotler SJ. Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach. Hepatology 2014;59:2422-3. [PMID: 24615976 DOI: 10.1002/hep.26772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
271 Nelson PW, Perelson AS. Mathematical analysis of delay differential equation models of HIV-1 infection. Mathematical Biosciences 2002;179:73-94. [DOI: 10.1016/s0025-5564(02)00099-8] [Cited by in Crossref: 300] [Cited by in F6Publishing: 29] [Article Influence: 15.8] [Reference Citation Analysis]
272 Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 2009;49:32-8. [PMID: 19065674 DOI: 10.1002/hep.22586] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
273 Layden-almer J. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37:1343-50. [DOI: 10.1053/jhep.2003.50217] [Cited by in Crossref: 146] [Cited by in F6Publishing: 124] [Article Influence: 8.1] [Reference Citation Analysis]
274 Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-449. [PMID: 23140245 DOI: 10.1146/annurev-pharmtox-011112-140254] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
275 Yu ML, Dai CY, Chen SC, Lee LP, Hsieh MY, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chang WY, Chuang WL. High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infect Dis 2005;5:27. [PMID: 15823212 DOI: 10.1186/1471-2334-5-27] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
276 Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, Mchutchison JG, Subramanian GM. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. Journal of Hepatology 2006;44:671-8. [DOI: 10.1016/j.jhep.2005.12.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
277 Van Vlierberghe H, Leroux-Roels G, Adler M, Bourgeois N, Nevens F, Horsmans Y, Brouwer J, Colle I, Delwaide J, Brenard R, Bastens B, Henrion J, de Vries RA, de Galocsy C, Michielsen P, Robaeys G, Bruckers L. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial. J Viral Hepat 2003;10:460-6. [PMID: 14633181 DOI: 10.1046/j.1365-2893.2003.00466.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
278 Furusyo N, Murata M, Ogawa E, Toyoda K, Ihara T, Ikezaki H, Hayashi T, Koga T, Kainuma M, Hayashi J. Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Journal of Antimicrobial Chemotherapy 2011;66:1127-39. [DOI: 10.1093/jac/dkr034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
279 Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams R, Zeuzem S, Naoumov NV. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005;43:776-82. [PMID: 16139918 DOI: 10.1016/j.jhep.2005.05.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
280 Lee S, Chakkarapani SK, Yeung ES, Kang SH. Direct quantitative screening of influenza A virus without DNA amplification by single-particle dual-mode total internal reflection scattering. Biosensors and Bioelectronics 2017;87:842-9. [DOI: 10.1016/j.bios.2016.09.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
281 Heystek HC, den Drijver B, Kapsenberg ML, van Lier RA, de Jong EC. Type I IFNs differentially modulate IL-12p70 production by human dendritic cells depending on the maturation status of the cells and counteract IFN-gamma-mediated signaling. Clin Immunol 2003;107:170-7. [PMID: 12804530 DOI: 10.1016/s1521-6616(03)00060-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
282 Retout S, Comets E, Samson A, Mentré F. Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates. Statist Med 2007;26:5162-79. [DOI: 10.1002/sim.2910] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
283 Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012;56:1019-24. [PMID: 22245888 DOI: 10.1016/j.jhep.2011.12.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
284 Rajagopalan R, Misialek S, Stevens SK, Myszka DG, Brandhuber BJ, Ballard JA, Andrews SW, Seiwert SD, Kossen K. Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior. Biochemistry 2009;48:2559-68. [DOI: 10.1021/bi900038p] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
285 Thomas HC, Török ME, Foster GR. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Hepatology. 1999;29:1333-1334. [PMID: 10094985 DOI: 10.1002/hep.510290453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
286 Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs 2008;68:791-801. [PMID: 18416586 DOI: 10.2165/00003495-200868060-00005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
287 Byrnes A, Ma X, Cuomo P, Park K, Wahl L, Wolf S, Zhou H, Trinchieri G, Karp C. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol 2001;31:2026-34. [DOI: 10.1002/1521-4141(200107)31:7<2026::aid-immu2026>3.0.co;2-u] [Cited by in Crossref: 59] [Article Influence: 3.0] [Reference Citation Analysis]
288 Gale M, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and Oncogenic Potentials of Hepatitis C Virus Are Linked to Interferon Resistance by Viral Repression of the PKR Protein Kinase. J Virol 1999;73:6506-16. [DOI: 10.1128/jvi.73.8.6506-6516.1999] [Cited by in Crossref: 195] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
289 Jessner W, Strasser M, Graziadei I, Berr F, Vogel W. Sustained remission of chronic hepatitis C after acute hepatitis B superinfection. Scand J Infect Dis. 2006;38:818-821. [PMID: 16938741 DOI: 10.1080/00365540600606523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
290 Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634-651. [PMID: 18715665 DOI: 10.1016/j.jhep.2008.07.013] [Cited by in Crossref: 225] [Cited by in F6Publishing: 212] [Article Influence: 17.3] [Reference Citation Analysis]
291 Dearborn AD, Marcotrigiano J. Hepatitis C Virus Structure: Defined by What It Is Not. Cold Spring Harb Perspect Med 2020;10:a036822. [PMID: 31501263 DOI: 10.1101/cshperspect.a036822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
292 Feliu A, Carrión JA, Massaguer A, Martínez-Bauer E, García-Retortillo M, González P, Costa J, Sánchez-Tapias JM, Forns X. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. J Viral Hepat. 2006;13:544-551. [PMID: 16901285 DOI: 10.1111/j.1365-2893.2006.00714.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
293 Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat. 2005;12:380-385. [PMID: 15985008 DOI: 10.1111/j.1365-2893.2005.00604.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
294 Elaiw AM, Alshaikh MA. Global stability of discrete virus dynamics models with humoural immunity and latency. Journal of Biological Dynamics 2019;13:639-74. [DOI: 10.1080/17513758.2019.1683630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
295 Chakrabarty SP. Optimal efficacy of ribavirin in the treatment of hepatitis C: EFFICACY OF RIBAVIRIN IN THE TREATMENT OF HEPATITIS C. Optim Control Appl Meth 2009;30:594-600. [DOI: 10.1002/oca.894] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
296 Sallie R. Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation. Virol J 2005;2:10. [PMID: 15707489 DOI: 10.1186/1743-422X-2-10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
297 Di Bisceglie AM, Fan X, Chambers T, Strinko J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responder. J Med Virol 2006;78:446-51. [DOI: 10.1002/jmv.20560] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
298 Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967-972. [PMID: 16107837 DOI: 10.1038/nature04082] [Cited by in Crossref: 689] [Cited by in F6Publishing: 621] [Article Influence: 43.1] [Reference Citation Analysis]
299 Goutelle S, Bourguignon L, Jelliffe RW, Conte JE Jr, Maire P. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin. J Theor Biol 2011;282:80-92. [PMID: 21605569 DOI: 10.1016/j.jtbi.2011.05.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
300 Prabhu RA, Nair S, Pai G, Reddy NP, Suvarna D. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database Syst Rev 2015;:CD007003. [PMID: 26287983 DOI: 10.1002/14651858.CD007003.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
301 Ikeda H, de Boer RJ, Sato K, Morita S, Misawa N, Koyanagi Y, Aihara K, Iwami S. Improving the estimation of the death rate of infected cells from time course data during the acute phase of virus infections: application to acute HIV-1 infection in a humanized mouse model. Theor Biol Med Model 2014;11:22. [PMID: 24885827 DOI: 10.1186/1742-4682-11-22] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
302 Shudo E, Ribeiro RM, Perelson AS. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat 2008;15:357-62. [PMID: 18380660 DOI: 10.1111/j.1365-2893.2007.00954.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
303 Rong L, Ribeiro RM, Perelson AS. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol 2012;74:1789-817. [PMID: 22639338 DOI: 10.1007/s11538-012-9736-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
304 Best K, Perelson AS. Mathematical modeling of within-host Zika virus dynamics. Immunol Rev 2018;285:81-96. [PMID: 30129207 DOI: 10.1111/imr.12687] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
305 Pugnale P, Herrmann E, Neumann AU, Pawlotsky JM, Schalm SW, Ferrari C, Homburger Y, Zeuzem S, Negro F; DITTO-HCV Study Group. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy. J Hepatol 2008;48:932-8. [PMID: 18433918 DOI: 10.1016/j.jhep.2008.02.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
306 Wolf DG, Shimoni A, Resnick IB, Stamminger T, Neumann AU, Chou S, Efferth T, Caplan O, Rose J, Nagler A, Marschall M. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6. [PMID: 21443904 DOI: 10.1016/j.antiviral.2011.03.184] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
307 Tsubota A, Satoh K, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, Fujise K, Tajiri H. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. World J Gastroenterol 2008;14:7220-4. [PMID: 19084937 DOI: 10.3748/wjg.14.7220] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
308 Lawitz E, Jacobson IM, Nelson DR, Zeuzem S, Sulkowski MS, Esteban R, Brainard D, McNally J, Symonds WT, McHutchison JG, Dieterich D, Gane E. Development of sofosbuvir for the treatment of hepatitis C virus infection. Ann N Y Acad Sci 2015;1358:56-67. [PMID: 26235748 DOI: 10.1111/nyas.12832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
309 Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909. [PMID: 16495249 DOI: 10.1128/AAC.50.3.899-909.2006] [Cited by in Crossref: 289] [Cited by in F6Publishing: 82] [Article Influence: 19.3] [Reference Citation Analysis]
310 Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:S145-51. [PMID: 12407588 DOI: 10.1053/jhep.2002.36798] [Cited by in Crossref: 16] [Cited by in F6Publishing: 30] [Article Influence: 0.8] [Reference Citation Analysis]
311 Shi R, Cui Y. Global analysis of a mathematical model for Hepatitis C virus transmissions. Virus Research 2016;217:8-17. [DOI: 10.1016/j.virusres.2016.02.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
312 Arends JE, Fransen JH, Hoepelman AI, van Baarle D. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. Int J Antimicrob Agents. 2011;38:538-539. [PMID: 21974859 DOI: 10.1016/j.ijantimicag.2011.08.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
313 Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. Hepat Med. 2010;2010:125-145. [PMID: 21331152 DOI: 10.2147/hmer.s7193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
314 Watabe T, Kishino H. Structural considerations in the fitness landscape of a virus. Mol Biol Evol. 2010;27:1782-1791. [PMID: 20194425 DOI: 10.1093/molbev/msq056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
315 Yu J, Karcher H, Feire AL, Lowe PJ. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 2011;13:169-78. [PMID: 21336535 DOI: 10.1208/s12248-011-9256-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
316 Brass V, Blum HE, Moradpour D. Recent developments in target identification against hepatitis C virus. Expert Opinion on Therapeutic Targets 2005;8:295-307. [DOI: 10.1517/14728222.8.4.295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
317 Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, Rice CM, Walker CM, Grakoui A. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 2008;4:e1000143. [PMID: 18773115 DOI: 10.1371/journal.ppat.1000143] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 5.0] [Reference Citation Analysis]
318 Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology. 2007;133:1132-1143. [PMID: 17919489 DOI: 10.1053/j.gastro.2007.06.059] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
319 Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. Exploring cell tropism as a possible contributor to influenza infection severity. PLoS One 2010;5:e13811. [PMID: 21124892 DOI: 10.1371/journal.pone.0013811] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
320 Pivert A, Payan C, Morand P, Fafi-Kremer S, Deshayes J, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin. J Clin Microbiol 2006;44:417-22. [PMID: 16455894 DOI: 10.1128/JCM.44.2.417-422.2006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
321 Browne EP, Letham B, Rudin C. A Computational Model of Inhibition of HIV-1 by Interferon-Alpha. PLoS One 2016;11:e0152316. [PMID: 27010978 DOI: 10.1371/journal.pone.0152316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
322 Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006;43:943-53. [PMID: 16761329 DOI: 10.1002/hep.21136] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
323 Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 2011;17:419-432. [PMID: 21274371 DOI: 10.3748/wjg.v17.i4.419] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
324 Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sidney J, Sette A, Pardoll D, Thomas DL, Ray SC. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med. 2005;201:1741-1752. [PMID: 15939790 DOI: 10.1084/jem.20050121] [Cited by in Crossref: 225] [Cited by in F6Publishing: 215] [Article Influence: 14.1] [Reference Citation Analysis]
325 Elaiw AM, Alghamdi MA, Aly S. Hepatitis B Virus Dynamics: Modeling, Analysis, and Optimal Treatment Scheduling. Discrete Dynamics in Nature and Society 2013;2013:1-9. [DOI: 10.1155/2013/712829] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
326 Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut. 1999;44:759-764. [PMID: 10205220 DOI: 10.1136/gut.44.5.759] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
327 Fukutomi T, Nakamuta M, Fukutomi M, Iwao M, Watanabe H, Hiroshige K, Tanabe Y, Nawata H. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol. 2001;34:100-107. [PMID: 11211884 DOI: 10.1016/S0168-8278(00)00044-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
328 Yang Y, Zou L, Ruan S. Global dynamics of a delayed within-host viral infection model with both virus-to-cell and cell-to-cell transmissions. Math Biosci 2015;270:183-91. [PMID: 25998145 DOI: 10.1016/j.mbs.2015.05.001] [Cited by in Crossref: 82] [Cited by in F6Publishing: 21] [Article Influence: 13.7] [Reference Citation Analysis]
329 Perelson AS, Ke R. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. Clin Pharmacol Ther 2021;109:829-40. [PMID: 33410134 DOI: 10.1002/cpt.2160] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
330 Graw F, Perelson AS. Modeling Viral Spread. Annu Rev Virol 2016;3:555-72. [PMID: 27618637 DOI: 10.1146/annurev-virology-110615-042249] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
331 Hadziyannis AS, Papaioannou C, Spanou F, Manesis EK, Hadziyannis SJ. Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit: INDUCTION TREATMENT FOR CHRONIC HEPATITIS C. Alimentary Pharmacology & Therapeutics 2001;15:551-7. [DOI: 10.1046/j.1365-2036.2001.00946.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
332 Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, Layden TJ, Cotler SJ, Barone AA. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat 2011;18:e52-60. [PMID: 20738775 DOI: 10.1111/j.1365-2893.2010.01358.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
333 Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004;85:3173-88. [PMID: 15483230 DOI: 10.1099/vir.0.80401-0] [Cited by in Crossref: 590] [Cited by in F6Publishing: 566] [Article Influence: 34.7] [Reference Citation Analysis]
334 Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279:17508-14. [PMID: 14766754 DOI: 10.1074/jbc.M313020200] [Cited by in Crossref: 218] [Cited by in F6Publishing: 69] [Article Influence: 12.8] [Reference Citation Analysis]
335 Nelson B, Adams J, Kuglstatter A, Li Z, Harris SF, Liu Y, Bohini S, Ma H, Klumpp K, Gao J, Sidhu SS. Structure-Guided Combinatorial Engineering Facilitates Affinity and Specificity Optimization of Anti-CD81 Antibodies. J Mol Biol 2018;430:2139-52. [PMID: 29778602 DOI: 10.1016/j.jmb.2018.05.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
336 Laskus T, Wilkinson J, Gallegos-orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004;127:764-76. [DOI: 10.1053/j.gastro.2004.06.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
337 Mangia A, Mottola L, Piazzolla V. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection. Clin Infect Dis 2013;56:1294-300. [PMID: 23271787 DOI: 10.1093/cid/cis1195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
338 Wedemeyer H, Wiegand J, Cornberg M, Manns MP. Polyethylene glycol-interferon: Current status in hepatitis C virus therapy: PEG-IFN: Current status in HCV therapy. Journal of Gastroenterology and Hepatology 2002;17:S344-50. [DOI: 10.1046/j.1440-1746.17.s3.26.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
339 Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol. 2002;14:1007-1011. [PMID: 12352221 DOI: 10.1097/00042737-200209000-00012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
340 Kim TY. The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection. Korean J Hepatol 2012;18:29-31. [PMID: 22511900 DOI: 10.3350/kjhep.2012.18.1.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
341 Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS. 2007;21:1855-1865. [PMID: 17721093 DOI: 10.1097/qad.0b013e32825eaba7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
342 Hass HG, Kreysel C, Fischinger J, Menzel J, Kaiser S. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. World J Gastroenterol 2005;11:5342-6. [PMID: 16149143 DOI: 10.3748/wjg.v11.i34.5342] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
343 Han C, Chaloner K. D- and c-optimal designs for exponential regression models used in viral dynamics and other applications. Journal of Statistical Planning and Inference 2003;115:585-601. [DOI: 10.1016/s0378-3758(02)00175-1] [Cited by in Crossref: 38] [Article Influence: 2.1] [Reference Citation Analysis]
344 Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol. 2003;55:360-367. [PMID: 12680884 DOI: 10.1046/j.1365-2125.2003.01780.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
345 Dahl G, Akerud T. Pharmacokinetics and the drug–target residence time concept. Drug Discovery Today 2013;18:697-707. [DOI: 10.1016/j.drudis.2013.02.010] [Cited by in Crossref: 139] [Cited by in F6Publishing: 102] [Article Influence: 17.4] [Reference Citation Analysis]
346 Kamiya N, Iwao E, Hiraga N, Tsuge M, Imamura M, Takahashi S, Miyoshi S, Tateno C, Yoshizato K, Chayama K. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. Journal of General Virology 2010;91:1668-77. [DOI: 10.1099/vir.0.019315-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
347 Kitagawa K, Kuniya T, Nakaoka S, Asai Y, Watashi K, Iwami S. Mathematical Analysis of a Transformed ODE from a PDE Multiscale Model of Hepatitis C Virus Infection. Bull Math Biol 2019;81:1427-41. [PMID: 30644067 DOI: 10.1007/s11538-018-00564-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
348 Rahman F, Rehermann B. Ethnicity and hepatitis C virus infection. Clin Gastroenterol Hepatol 2004;2:456-8. [PMID: 15181611 DOI: 10.1016/s1542-3565(04)00161-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
349 Salloum S, Oniangue-Ndza C, Neumann-Haefelin C, Hudson L, Giugliano S, aus dem Siepen M, Nattermann J, Spengler U, Lauer GM, Wiese M, Klenerman P, Bright H, Scherbaum N, Thimme R, Roggendorf M, Viazov S, Timm J. Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol 2008;82:11803-12. [PMID: 18815309 DOI: 10.1128/JVI.00997-08] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
350 Kumberger P, Frey F, Schwarz US, Graw F. Multiscale modeling of virus replication and spread. FEBS Lett 2016;590:1972-86. [PMID: 26878104 DOI: 10.1002/1873-3468.12095] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
351 Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, Demicco MP, Rodriguez-torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-talavera JC, Grasela DM. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:1956-65. [DOI: 10.1002/hep.24609] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 13.9] [Reference Citation Analysis]
352 Pugnale P, Latorre P, Rossi C, Crovatto K, Pazienza V, Gottardi AD, Negro F. Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells. J Virol Methods. 2006;133:195-204. [PMID: 16384611 DOI: 10.1016/j.jviromet.2005.11.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
353 Franco S, Parera M, Aparicio E, Clotet B, Martinez MA. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology. 2007;45:899-910. [PMID: 17393500 DOI: 10.1002/hep.21623] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
354 Smith AP, Moquin DJ, Bernhauerova V, Smith AM. Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral Decay. Front Microbiol 2018;9:1554. [PMID: 30042759 DOI: 10.3389/fmicb.2018.01554] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
355 Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D, Maurel P, Pawlotsky JM. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol. 2002;76:8189-8199. [PMID: 12134024 DOI: 10.1128/jvi.76.16.8189-8199.2002] [Cited by in Crossref: 90] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
356 Nanda S, Moore H, Lenhart S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 2007;210:143-56. [PMID: 17599363 DOI: 10.1016/j.mbs.2007.05.003] [Cited by in Crossref: 64] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
357 Emery VC. Cytomegalovirus and the aging population. Drugs Aging. 2001;18:927-933. [PMID: 11888347 DOI: 10.2165/00002512-200118120-00004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
358 Bielejec F, Baele G, Rodrigo AG, Suchard MA, Lemey P. Identifying predictors of time-inhomogeneous viral evolutionary processes. Virus Evol 2016;2:vew023. [PMID: 27774306 DOI: 10.1093/ve/vew023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
359 Larrubia JR, Moreno-Cubero E, Miquel J, Sanz-de-Villalobos E. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol. 2015;21:3480-3491. [PMID: 25834312 DOI: 10.3748/wjg.v21.i12.3480] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
360 May MM, Lorengel H, Kreuter J, Zimmermann H, Ruebsamen-Schaeff H, Urban A. RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities. Biochim Biophys Acta 2011;1814:1325-32. [PMID: 21621653 DOI: 10.1016/j.bbapap.2011.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
361 Ireton RC, Gale M. Systems Biology Analyses to Define Host Responses to HCV Infection and Therapy. In: Katze MG, editor. Systems Biology. Berlin: Springer Berlin Heidelberg; 2013. pp. 143-67. [DOI: 10.1007/82_2012_251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
362 Padmanabhan P, Dixit NM. Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus. PLoS One 2012;7:e36107. [PMID: 22545157 DOI: 10.1371/journal.pone.0036107] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
363 Carbone M, Cockwell P, Neuberger J. Hepatitis C and kidney transplantation. Int J Nephrol. 2011;2011:593291. [PMID: 21755059 DOI: 10.4061/2011/593291] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
364 Belema M, Nguyen VN, St. Laurent DR, Lopez OD, Qiu Y, Good AC, Nower PT, Valera L, O’boyle DR, Sun J, Liu M, Fridell RA, Lemm JA, Gao M, Knipe JO, Meanwell NA, Snyder LB. HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives. Bioorganic & Medicinal Chemistry Letters 2013;23:4428-35. [DOI: 10.1016/j.bmcl.2013.05.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
365 Khoury DS, Aogo R, Randriafanomezantsoa-Radohery G, McCaw JM, Simpson JA, McCarthy JS, Haque A, Cromer D, Davenport MP. Within-host modeling of blood-stage malaria. Immunol Rev 2018;285:168-93. [PMID: 30129195 DOI: 10.1111/imr.12697] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
366 Werner JM, Serti E, Chepa-Lotrea X, Stoltzfus J, Ahlenstiel G, Noureddin M, Feld JJ, Liang TJ, Rotman Y, Rehermann B. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology. 2014;60:1160-1169. [PMID: 24700342 DOI: 10.1002/hep.27092] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
367 Ullerich H, Avenhaus W, Poremba C, Domschke W, Menzel J. High-dose interferon α-2a with ribavirin and amantadine in naïve chronic hepatitis C patients - results of a randomized, prospective, pilot study: HIGH-DOSE INTERFERON-α IN HEPATITIS C. Alimentary Pharmacology & Therapeutics 2002;16:2107-14. [DOI: 10.1046/j.1365-2036.2002.01379.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
368 Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N. Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol. 2018;90:942-950. [PMID: 29315640 DOI: 10.1002/jmv.25022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
369 Theodore D, Shiffman ML, Sterling RK, Bruno CJ, Weinstein J, Crippin JS, Garcia G, Wright TL, Conjeevaram H, Reddy RK, Nolte FS, Fried MW. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003;48:140-5. [PMID: 12645801 DOI: 10.1023/a:1021750818611] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
370 Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Mita K, Hotta H, Shouji I, El-shamy A, Kawada N, Kudo M, Hayashi Y. Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b. Intervirology 2008;51:70-5. [DOI: 10.1159/000122601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
371 Chatterjee AN, Basir FA, Takeuchi Y. Effect of DAA therapy in hepatitis C treatment - an impulsive control approach. Math Biosci Eng 2021;18:1450-64. [PMID: 33757193 DOI: 10.3934/mbe.2021075] [Reference Citation Analysis]
372 Honda M, Nakamura M, Tateno M, Sakai A, Shimakami T, Shirasaki T, Yamashita T, Arai K, Yamashita T, Sakai Y. Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C. J Hepatol. 2010;53:817-826. [PMID: 20739080 DOI: 10.1016/j.jhep.2010.04.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
373 Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology. 2015;62:1623-1632. [PMID: 26095927 DOI: 10.1002/hep.27934] [Cited by in Crossref: 208] [Cited by in F6Publishing: 194] [Article Influence: 34.7] [Reference Citation Analysis]
374 Mihm U, Gärtner BC, Faust D, Hofmann WP, Sarrazin C, Zeuzem S, Herrmann E. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J Hepatol 2005;43:217-24. [PMID: 15964093 DOI: 10.1016/j.jhep.2005.02.037] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
375 Ciupe SM, Heffernan JM. In-host modeling. Infect Dis Model 2017;2:188-202. [PMID: 29928736 DOI: 10.1016/j.idm.2017.04.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
376 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
377 Souza MO, Zubelli JP. Global stability for a class of virus models with cytotoxic T lymphocyte immune response and antigenic variation. Bull Math Biol 2011;73:609-25. [PMID: 20464520 DOI: 10.1007/s11538-010-9543-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
378 Yu ML, Hou NJ, Dai CY, Chang WY, Chuang WL. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin. Antimicrob Agents Chemother 2005;49:3986-7. [PMID: 16127091 DOI: 10.1128/AAC.49.9.3986-3987.2005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
379 Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554-1568. [PMID: 12016423 DOI: 10.1053/gast.2002.33428] [Cited by in Crossref: 157] [Cited by in F6Publishing: 137] [Article Influence: 8.3] [Reference Citation Analysis]
380 Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61:2263-2288. [PMID: 11772139 DOI: 10.2165/00003495-200161150-00013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
381 Brook CE, Boots M, Chandran K, Dobson AP, Drosten C, Graham AL, Grenfell BT, Müller MA, Ng M, Wang LF, van Leeuwen A. Accelerated viral dynamics in bat cell lines, with implications for zoonotic emergence. Elife 2020;9:e48401. [PMID: 32011232 DOI: 10.7554/eLife.48401] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 48.0] [Reference Citation Analysis]
382 Zhang J, Lipton HL, Perelson AS, Dahari H. Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. J Virol 2013;87:4052-9. [PMID: 23365440 DOI: 10.1128/JVI.03395-12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
383 Wang S, Buchli R, Schiller J, Gao J, VanGundy RS, Hildebrand WH, Eckels DD. Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity. World J Gastroenterol 2010;16:1953-69. [PMID: 20419832 DOI: 10.3748/wjg.v16.i16.1953] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
384 Bekkering FC, Brouwer JT, Hansen BE, Schalm SW. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. Journal of Hepatology 2001;34:435-40. [DOI: 10.1016/s0168-8278(00)00033-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
385 Hartlage AS, Cullen JM, Kapoor A. The Strange, Expanding World of Animal Hepaciviruses. Annu Rev Virol 2016;3:53-75. [PMID: 27741408 DOI: 10.1146/annurev-virology-100114-055104] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
386 Gremion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol. 2005;15:235-268. [PMID: 15782389 DOI: 10.1002/rmv.466] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 4.2] [Reference Citation Analysis]
387 Zhang Y, Liu Y, Zhao Y, Shi L, Ma L, Yan H, Wu H, Wei L, Dong T, Chen X. Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients. Liver Int 2012;32:102-9. [PMID: 22098382 DOI: 10.1111/j.1478-3231.2011.02652.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 White PW, Llinas-Brunet M, Bös M. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease. Prog Med Chem 2006;44:65-107. [PMID: 16697895 DOI: 10.1016/S0079-6468(05)44402-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
389 Andreone P, Cursaro C, Gramenzi A, Margotti M, Ferri E, Talarico S, Biselli M, Felline F, Tuthill C, Martins E, Gasbarrini G, Bernardi M. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat 2001;8:194-201. [PMID: 11380797 DOI: 10.1046/j.1365-2893.2001.00285.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
390 Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat. 2010;17:825-833. [PMID: 20723038 DOI: 10.1111/j.1365-2893.2010.01348.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
391 Elaiw A, Alshamrani N. Global stability of a delayed adaptive immunity viral infection with two routes of infection and multi-stages of infected cells. Communications in Nonlinear Science and Numerical Simulation 2020;86:105259. [DOI: 10.1016/j.cnsns.2020.105259] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
392 Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SKH. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem 2011;286:44218-33. [PMID: 22002064 DOI: 10.1074/jbc.M111.290783] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
393 Chen KX, Njoroge FG, Pichardo J, Prongay A, Butkiewicz N, Yao N, Madison V, Girijavallabhan V. Potent 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid-Based Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease. J Med Chem 2006;49:567-74. [DOI: 10.1021/jm050520a] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
394 Hügle T, Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med Virol 2003;13:361-71. [PMID: 14625884 DOI: 10.1002/rmv.397] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
395 Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR 2nd, Sun JH, Wang C, Fridell RA, Meanwell NA. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57:1643-1672. [PMID: 24621191 DOI: 10.1021/jm401793m] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
396 Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C. Hepatology. 2012;56:492-500. [PMID: 22334511 DOI: 10.1002/hep.25666] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
397 Dandri M, Murray JM, Lutgehetmann M, Volz T, Lohse AW, Petersen J. Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008;48:1079-86. [DOI: 10.1002/hep.22469] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
398 Krajden M. Diagnostic et test du virus de l’hépatite C. Can J Public Health 2000;91:S36-42. [DOI: 10.1007/bf03405108] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
399 Rodrigue-Gervais IG, Rigsby H, Jouan L, Willems B, Lamarre D. Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance. PLoS One. 2014;9:e102605. [PMID: 25033043 DOI: 10.1371/journal.pone.0102605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
400 Zhou Y, Bartels DJ, Hanzelka BL, Müh U, Wei Y, Chu HM, Tigges AM, Brennan DL, Rao BG, Swenson L, Kwong AD, Lin C. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008;52:110-20. [PMID: 17938182 DOI: 10.1128/AAC.00863-07] [Cited by in Crossref: 77] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
401 Rose J, Emery VC, Kumar D, Asberg A, Hartmann A, Jardine AG, Bignamini AA, Humar A, Neumann AU. Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathog 2017;13:e1006299. [PMID: 28406982 DOI: 10.1371/journal.ppat.1006299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
402 Perez R, Jimenez M, Crespo J, Diago M, Enriquez J, Vaquero P, Sola R, Olcoz JL, Romero M, Salmeron J, Blanco MI, Ona M, Melon S, Rodrigo L; Grupo Inter-Hospitalario Espanol. Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. J Viral Hepat 2003;10:437-45. [DOI: 10.1046/j.1365-2893.2003.00461.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
403 Ke R, Loverdo C, Qi H, Olson CA, Wu NC, Sun R, Lloyd-Smith JO. Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 2014;69:724-7. [PMID: 24169581 DOI: 10.1093/jac/dkt423] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
404 Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Res 2019;163:149-55. [PMID: 30711416 DOI: 10.1016/j.antiviral.2019.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
405 Schweitzer CJ, Liang TJ. Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry. ACS Infect Dis 2015;1:416-9. [PMID: 27617924 DOI: 10.1021/acsinfecdis.5b00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
406 Abel M, Sène D, Pol S, Bourlière M, Poynard T, Charlotte F, Cacoub P, Caillat-Zucman S. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology. 2006;44:1607-1616. [PMID: 17133491 DOI: 10.1002/hep.21438] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 6.4] [Reference Citation Analysis]
407 Tan A, Koh S, Bertoletti A. Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med. 2015;5:a021428. [PMID: 26134480 DOI: 10.1101/cshperspect.a021428] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
408 Rivett L, Alexander G. Is the conquest of Hepatitis C imminent? Expert Rev Mol Med 2019;21:e3. [PMID: 30909984 DOI: 10.1017/erm.2019.3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
409 Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002;36:S65-S73. [PMID: 12407578 DOI: 10.1002/hep.1840360709] [Cited by in Crossref: 110] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
410 Sun JH, O'Boyle Ii DR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012;55:1692-9. [PMID: 22234905 DOI: 10.1002/hep.25581] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
411 Reetoo KN, Osman SA, Illavia SJ, Banatvala JE, Muir P. Development and evaluation of quantitative-competitive PCR for quantitation of coxsackievirus B3 RNA in experimentally infected murine tissues. J Virol Methods 1999;82:145-56. [PMID: 10894631 DOI: 10.1016/s0166-0934(99)00093-2] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
412 Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76:11079-11090. [PMID: 12368350 DOI: 10.1128/jvi.76.21.11079-11090.2002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
413 Garmaroudi FS, Marchant D, Hendry R, Luo H, Yang D, Ye X, Shi J, Mcmanus BM. Coxsackievirus B3 replication and pathogenesis. Future Microbiology 2015;10:629-53. [DOI: 10.2217/fmb.15.5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 11.5] [Reference Citation Analysis]
414 Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012;142:790-795. [PMID: 22248659 DOI: 10.1053/j.gastro.2011.12.057] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 8.1] [Reference Citation Analysis]
415 Zeuzem S. Favourable and disappointing lessons from viral kinetics. Journal of Hepatology 2002;37:151-3. [DOI: 10.1016/s0168-8278(02)00167-8] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
416 Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat. 2002;9:340-345. [PMID: 12225328 DOI: 10.1046/j.1365-2893.2002.00377.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 3.0] [Reference Citation Analysis]
417 Ezelle HJ, Markovic D, Barber GN. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol. 2002;76:12325-12334. [PMID: 12414973 DOI: 10.1128/jvi.76.23.12325-12334.2002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
418 Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 2011;18:e325-31. [PMID: 21692944 DOI: 10.1111/j.1365-2893.2010.01425.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
419 Campo DS, Dimitrova Z, Yamasaki L, Skums P, Lau DT, Vaughan G, Forbi JC, Teo CG, Khudyakov Y. Next-generation sequencing reveals large connected networks of intra-host HCV variants. BMC Genomics 2014;15 Suppl 5:S4. [PMID: 25081811 DOI: 10.1186/1471-2164-15-S5-S4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 20] [Article Influence: 6.9] [Reference Citation Analysis]
420 Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol. 2011;92:2227-2236. [PMID: 21775583 DOI: 10.1099/vir.0.033910-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
421 Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol. 2002;97:700-706. [PMID: 11922566 DOI: 10.1111/j.1572-0241.2002.05555.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 104] [Article Influence: 6.4] [Reference Citation Analysis]
422 Tuckwell HC. Viral Population Growth Models. In: Armitage P, Colton T, editors. Encyclopedia of Biostatistics. Chichester: John Wiley & Sons, Ltd; 2005. [DOI: 10.1002/0470011815.b2a07058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
423 Saleh MI, Bani Melhim S. A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. J Chemother 2019;31:274-83. [PMID: 31070545 DOI: 10.1080/1120009X.2019.1609739] [Reference Citation Analysis]
424 Lindenbach BD, Rice CM. Evasive maneuvers by hepatitits C virus. Hepatology 2003;38:769-71. [DOI: 10.1002/hep.510380327] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
425 Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther 2015;20:149-55. [PMID: 24912382 DOI: 10.3851/IMP2806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
426 Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, Sherman KE; and the Multicenter Hemophilia Cohort Study Group. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005;105:533-41. [DOI: 10.1182/blood-2004-04-1452] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
427 Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One. 2012;7:e34372. [PMID: 22511937 DOI: 10.1371/journal.pone.0034372] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 7.6] [Reference Citation Analysis]
428 He XS, Nanda S, Ji X, Calderon-Rodriguez GM, Greenberg HB, Liang TJ. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. J Interferon Cytokine Res 2010;30:311-20. [PMID: 20038212 DOI: 10.1089/jir.2009.0082] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
429 Spitz N, Barros JJ, do Ó KM, Brandão-Mello CE, Araujo NM. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. Viruses 2019;11:E1000. [PMID: 31683566 DOI: 10.3390/v11111000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999;354:1782-1785. [PMID: 10577640 DOI: 10.1016/s0140-6736(99)02035-8] [Cited by in Crossref: 366] [Cited by in F6Publishing: 172] [Article Influence: 16.6] [Reference Citation Analysis]
431 Angus AG, Patel AH. Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiology 2011;6:279-94. [DOI: 10.2217/fmb.11.9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
432 Zhang Y, Guo D, Zhao Y, Chen X, Ma L, Jin Y, Yan H, Wu H, Wei L, Dong T, Chen X. The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection. Antiviral Res 2011;92:247-54. [PMID: 21889543 DOI: 10.1016/j.antiviral.2011.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
433 Dahari H, Cotler SJ, Layden TJ, Perelson AS. Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. J Hepatol 2013;58:840-2. [PMID: 23246507 DOI: 10.1016/j.jhep.2012.08.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
434 Qi H, Olson CA, Wu NC, Ke R, Loverdo C, Chu V, Truong S, Remenyi R, Chen Z, Du Y, Su SY, Al-Mawsawi LQ, Wu TT, Chen SH, Lin CY, Zhong W, Lloyd-Smith JO, Sun R. A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog 2014;10:e1004064. [PMID: 24722365 DOI: 10.1371/journal.ppat.1004064] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
435 Herring BL, Tsui R, Peddada L, Busch M, Delwart EL. Wide range of quasispecies diversity during primary hepatitis C virus infection. J Virol 2005;79:4340-6. [PMID: 15767434 DOI: 10.1128/JVI.79.7.4340-4346.2005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
436 Lake-Bakaar G, Ruffini L, Kuzmic P. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 2003;48:126-39. [PMID: 12645800 DOI: 10.1023/a:1021798701772] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
437 Churkin A, Lewkiewicz S, Reinharz V, Dahari H, Barash D. Efficient Methods for Parameter Estimation of Ordinary and Partial Differential Equation Models of Viral Hepatitis Kinetics. Mathematics (Basel) 2020;8:1483. [PMID: 33224865 DOI: 10.3390/math8091483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 2009;23:2439-50. [PMID: 19898214 DOI: 10.1097/QAD.0b013e32832ff1c0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
439 Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol. 2000;33:313-322. [PMID: 10952250 DOI: 10.1016/s0168-8278(00)80373-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
440 González-Parra G, Dobrovolny HM, Aranda DF, Chen-Charpentier B, Guerrero Rojas RA. Quantifying rotavirus kinetics in the REH tumor cell line using in vitro data. Virus Res 2018;244:53-63. [PMID: 29109019 DOI: 10.1016/j.virusres.2017.09.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
441 Bertacchi D, Zucca F, Foresti S, Mangioni D, Gori A. Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. Math Med Biol 2015;32:383-403. [PMID: 25398978 DOI: 10.1093/imammb/dqu022] [Reference Citation Analysis]
442 Song X, Neumann AU. Global stability and periodic solution of the viral dynamics. Journal of Mathematical Analysis and Applications 2007;329:281-97. [DOI: 10.1016/j.jmaa.2006.06.064] [Cited by in Crossref: 150] [Cited by in F6Publishing: 50] [Article Influence: 10.7] [Reference Citation Analysis]
443 Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Scand J Infect Dis 2010;42:896-901. [PMID: 20608766 DOI: 10.3109/00365548.2010.498019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
444 Benson N, de Jongh J, Duckworth JD, Jones HM, Pertinez HE, Rawal JK, van Steeg TJ, Van der Graaf PH. Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice. Antimicrob Agents Chemother 2010;54:1179-85. [PMID: 20028817 DOI: 10.1128/AAC.00551-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
445 Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007;46:16-21. [PMID: 17596864 DOI: 10.1002/hep.21657] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
446 Di Lello FA, Culasso AC, Campos RH. Inter and intrapatient evolution of hepatitis C virus. Annals of Hepatology 2015;14:442-9. [DOI: 10.1016/s1665-2681(19)31164-0] [Cited by in Crossref: 8] [Article Influence: 1.3] [Reference Citation Analysis]
447 Sallie R. Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. Virol J 2005;2:70. [PMID: 16115320 DOI: 10.1186/1743-422X-2-70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
448 Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs 2008;68:27-42. [PMID: 18081371 DOI: 10.2165/00003495-200868010-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
449 Berenguer M, Wright TL. Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. Clinics in Liver Disease 2003;7:631-50. [DOI: 10.1016/s1089-3261(03)00059-x] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
450 Koutsoudakis G, Forns X, Pérez-Del-Pulgar S. [The molecular biology of hepatitis C virus]. Gastroenterol Hepatol. 2013;36:280-293. [PMID: 23490024 DOI: 10.1016/j.gastrohep.2012.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
451 Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930-936. [PMID: 11915041 DOI: 10.1053/jhep.2002.32150] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 4.5] [Reference Citation Analysis]
452 Enomoto M, Nishiguchi S, Kohmoto M, Tamori A, Habu D, Takeda T, Seki S, Shiomi S. Effects of ribavirin combined with interferon-alpha2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. J Viral Hepat 2004;11:448-54. [DOI: 10.1111/j.1365-2893.2004.00524.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
453 Pawlotsky J. Hepatitis C: It’s a long way to new therapy, it’s a long way to go…. Gastroenterology 2004;127:1629-32. [DOI: 10.1053/j.gastro.2004.09.059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
454 Cento V, Tontodonati M, Di Maio VC, Bellocchi MC, Valenti F, Manunta A, Fortuna S, Armenia D, Carioti L, Antonucci FP, Bertoli A, Trave F, Cacciatore P, Angelico M, Navarra P, Neumann AU, Vecchiet J, Parruti G, Babudieri S, Perno CF, Ceccherini-Silberstein F. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. Dig Liver Dis 2015;47:233-41. [PMID: 25637450 DOI: 10.1016/j.dld.2014.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
455 Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2005;75:27-34. [PMID: 15543591 DOI: 10.1002/jmv.20232] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
456 Mixson-hayden T, Dawson GJ, Teshale E, Le T, Cheng K, Drobeniuc J, Ward J, Kamili S. Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users. Journal of Clinical Virology 2015;66:15-8. [DOI: 10.1016/j.jcv.2015.02.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
457 Powdrill MH, Bernatchez JA, Götte M. Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B. Viruses 2010;2:2169-95. [PMID: 21994615 DOI: 10.3390/v2102169] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
458 Zeuzem S. Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons? Journal of Hepatology 2004;41:488-90. [DOI: 10.1016/j.jhep.2004.07.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
459 Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother. 2004;48:4784-4792. [PMID: 15561857 DOI: 10.1128/AAC.48.12.4784-4792.2004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
460 Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology. 2010;139:965-974. [PMID: 20621699 DOI: 10.1053/j.gastro.2010.05.077] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 6.7] [Reference Citation Analysis]
461 Jakupciak JP, Colwell RR. Biological agent detection technologies. Mol Ecol Resour 2009;9 Suppl s1:51-7. [PMID: 21564964 DOI: 10.1111/j.1755-0998.2009.02632.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
462 Flint M, Mullen S, Deatly AM, Chen W, Miller LZ, Ralston R, Broom C, Emini EA, Howe AY. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 2009;53:401-11. [PMID: 18936191 DOI: 10.1128/AAC.01081-08] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
463 Rehermann B. 8 Immunopathogenesis of hepatitis C. Hepatitis C. Elsevier; 2000. pp. 147-68. [DOI: 10.1016/s1874-5326(00)80012-5] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
464 Chen KX, Njoroge FG, Pichardo J, Prongay A, Butkiewicz N, Yao N, Madison V, Girijavallabhan V. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease. J Med Chem 2005;48:6229-35. [PMID: 16190750 DOI: 10.1021/jm050323b] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
465 Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 2010;105:989-1004; quiz 988, 1005. [PMID: 20087331 DOI: 10.1038/ajg.2009.726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
466 Clausznitzer D, Harnisch J, Kaderali L. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals. Virus Res 2016;218:96-101. [PMID: 26409026 DOI: 10.1016/j.virusres.2015.09.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
467 Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015;35:1923-33. [PMID: 25939775 DOI: 10.1111/liv.12861] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
468 Domingo E. Interaction of virus populations with their hosts. Virus as Populations. Elsevier; 2020. pp. 123-66. [DOI: 10.1016/b978-0-12-816331-3.00004-0] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
469 Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, Neumann-Fraune M, Beggel B, Walker A, Timm J. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. PLoS One. 2016;11:e0155869. [PMID: 27196673 DOI: 10.1371/journal.pone.0155869] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 13.6] [Reference Citation Analysis]
470 Caridade M, Oliveira VG, Agua-Doce A, Graca L, Ribeiro RM. The fate of CD4+ T cells under tolerance-inducing stimulation: a modeling perspective. Immunol Cell Biol 2013;91:652-60. [PMID: 24145855 DOI: 10.1038/icb.2013.63] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
471 Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasispecies heterogeneity and constraints on the evolution of the 5’ noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology. 2002;298:160-173. [PMID: 12093183 DOI: 10.1006/viro.2002.1494] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
472 Curran R, Jameson CL, Craggs JK, Grabowska AM, Thomson BJ, Robins A, Irving WL, Ball JK. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. Journal of General Virology 2002;83:11-23. [DOI: 10.1099/0022-1317-83-1-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
473 Lin K. Development of novel antiviral therapies for hepatitis C virus. Virol Sin 2010;25:246-66. [PMID: 20960299 DOI: 10.1007/s12250-010-3140-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
474 Torres-Puente M, Bracho MA, Jiménez N, García-Robles I, Moya A, González-Candelas F. Sampling and repeatability in the evaluation of hepatitis C virus genetic variability. J Gen Virol 2003;84:2343-50. [PMID: 12917454 DOI: 10.1099/vir.0.19273-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
475 Shapira MY, Resnick IB, Chou S, Neumann AU, Lurain NS, Stamminger T, Caplan O, Saleh N, Efferth T, Marschall M, Wolf DG. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008;46:1455-7. [PMID: 18419454 DOI: 10.1086/587106] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 8.9] [Reference Citation Analysis]
476 González-Parra G, Dobrovolny HM. Assessing Uncertainty in A2 Respiratory Syncytial Virus Viral Dynamics. Comput Math Methods Med 2015;2015:567589. [PMID: 26451163 DOI: 10.1155/2015/567589] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
477 Bush CO, Greenstein AE, Delaney WE 4th, Beran RK. Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures. PLoS One 2013;8:e65273. [PMID: 23755208 DOI: 10.1371/journal.pone.0065273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
478 Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007;25:1411-9. [PMID: 18066038 DOI: 10.1038/nbt1364] [Cited by in Crossref: 167] [Cited by in F6Publishing: 135] [Article Influence: 12.8] [Reference Citation Analysis]
479 Daun S, Clermont G. In Silico Modeling in Infectious Disease. Drug Discov Today Dis Models 2007;4:117-22. [PMID: 19707291 DOI: 10.1016/j.ddmod.2007.09.001] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
480 Shapiro M, Duca KA, Lee K, Delgado-Eckert E, Hawkins J, Jarrah AS, Laubenbacher R, Polys NF, Hadinoto V, Thorley-Lawson DA. A virtual look at Epstein-Barr virus infection: simulation mechanism. J Theor Biol 2008;252:633-48. [PMID: 18371986 DOI: 10.1016/j.jtbi.2008.01.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
481 Butler EK, McCullough J. Pathogen reduction combined with rapid diagnostic tests to reduce the risk of transfusion-transmitted infections in Uganda. Transfusion 2018;58:854-61. [PMID: 29405306 DOI: 10.1111/trf.14497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
482 Sguanci L, Bagnoli F, Liò P. Modeling HIV quasispecies evolutionary dynamics. BMC Evol Biol 2007;7 Suppl 2:S5. [PMID: 17767733 DOI: 10.1186/1471-2148-7-S2-S5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
483 Zhukova OB, Ryazantseva NV, Novitsky VV. Viral persistence: immunologic and molecular-genetic aspects of pathogenesis. Bûll sib med 2003;2:113-20. [DOI: 10.20538/1682-0363-2003-4-113-120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
484 Kieffer TL, George S. Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol. 2014;8:16-21. [PMID: 24852142 DOI: 10.1016/j.coviro.2014.04.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
485 Ferenci P. Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C. Digestive and Liver Disease 2003;35:601-6. [DOI: 10.1016/s1590-8658(03)00376-1] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
486 Shiina M, Kobayashi K, Satoh H, Niitsuma H, Ueno Y, Shimosegawa T. Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C. J Gastroenterol Hepatol. 2004;19:558-564. [PMID: 15086600 DOI: 10.1111/j.1440-1746.2003.03329.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
487 Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8. [PMID: 17030174 DOI: 10.1053/j.gastro.2006.07.022] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 9.3] [Reference Citation Analysis]
488 Halfon P, Neumann AU, Bourlière M, Rieu A, Chadapaud S, Khiri H, Ouzan D, Cacoub P. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat. 2003;10:351-353. [PMID: 12969186 DOI: 10.1046/j.1365-2893.2003.00433.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
489 Ke R, Li H, Wang S, Ding W, Ribeiro RM, Giorgi EE, Bhattacharya T, Barnard RJO, Hahn BH, Shaw GM, Perelson AS. Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proc Natl Acad Sci U S A 2018;115:E7139-48. [PMID: 29987026 DOI: 10.1073/pnas.1805267115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
490 Sears D, Davis GL. Natural History of Hepatitis C. Transplantation of the Liver. Elsevier; 2005. pp. 129-41. [DOI: 10.1016/b978-0-7216-0118-2.50014-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
491 Nair LG, Sannigrahi M, Bogen S, Pinto P, Chen KX, Prongay A, Tong X, Cheng K, Girijavallabhan V, George Njoroge F. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile. Bioorganic & Medicinal Chemistry Letters 2010;20:567-70. [DOI: 10.1016/j.bmcl.2009.11.094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
492 Torre F, Giusto R, Grasso A, Brizzolara R, Campo N, Sinelli N, Balestra V, Picciotto A. Clearance kinetics of hepatitis C virus under different antiviral therapies. J Med Virol. 2001;64:455-459. [PMID: 11468729 DOI: 10.1002/jmv.1071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
493 Layden TJ, Layden JE, Reddy KR, Levy-drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002;9:334-9. [DOI: 10.1046/j.1365-2893.2002.00376.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
494 Kim TH, Kim KA, Lim YS, Gwak G, Yoon J, Kang GH, Lee H. Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy. Intervirology 2005;48:230-8. [DOI: 10.1159/000084600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
495 Schwer B, Ren S, Pietschmann T, Kartenbeck J, Kaehlcke K, Bartenschlager R, Yen TS, Ott M. Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol. 2004;78:7958-7968. [PMID: 15254168 DOI: 10.1128/jvi.78.15.7958-7968.2004] [Cited by in Crossref: 118] [Cited by in F6Publishing: 66] [Article Influence: 6.9] [Reference Citation Analysis]
496 Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology 2000;32:889-96. [PMID: 11050035 DOI: 10.1053/jhep.2000.19150] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 4.6] [Reference Citation Analysis]
497 Li J, Men K, Yang Y, Li D. Dynamical analysis on a chronic hepatitis C virus infection model with immune response. J Theor Biol 2015;365:337-46. [PMID: 25451526 DOI: 10.1016/j.jtbi.2014.10.039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
498 Ardelean DS, Letarte M. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Front Genet 2015;6:35. [PMID: 25717337 DOI: 10.3389/fgene.2015.00035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
499 Dahari H, Guedj J, Perelson AS. Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved. Hepatology 2011;54:749. [PMID: 21433039 DOI: 10.1002/hep.24310] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
500 Steindl-munda P, Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Gangl A, Vogel W; for the Austrian Hepatitis Study Group. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy: High dose IFN in nonresponders and relapsers. Liver International 2003;23:269-75. [DOI: 10.1034/j.1600-0676.2003.00838.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
501 Sievert W, Batey RG. The treatment of hepatitis C. Medical Journal of Australia 1999;170:200-2. [DOI: 10.5694/j.1326-5377.1999.tb140315.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
502 Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med. 2013;158:235-245. [PMID: 23420232 DOI: 10.7326/0003-4819-158-4-201302190-00003] [Cited by in Crossref: 153] [Cited by in F6Publishing: 141] [Article Influence: 19.1] [Reference Citation Analysis]
503 Weinberger LS, Schaffer DV, Arkin AP. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol 2003;77:10028-36. [PMID: 12941913 DOI: 10.1128/jvi.77.18.10028-10036.2003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
504 Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:161. [PMID: 21477382 DOI: 10.1186/1743-422x-8-161] [Cited by in Crossref: 89] [Cited by in F6Publishing: 61] [Article Influence: 8.9] [Reference Citation Analysis]
505 Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006;23:1043-54. [DOI: 10.1111/j.1365-2036.2006.02863.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
506 Lawitz EJ, Membreno FE. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. J Gastroenterol Hepatol. 2014;29:1574-1581. [PMID: 24852401 DOI: 10.1111/jgh.12632] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
507 Ballesteros AL, Fuster D, Planas R, Clotet B, Tural C. Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. Journal of Antimicrobial Chemotherapy 2005;55:824-7. [DOI: 10.1093/jac/dki142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
508 Ghori NU, Shafique A, Hayat MQ, Anjum S. The Phylogeographic and Spatiotemporal Spread of HCV in Pakistani Population. PLoS One 2016;11:e0164265. [PMID: 27764129 DOI: 10.1371/journal.pone.0164265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
509 Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology. 2008;47:321-331. [PMID: 18161707 DOI: 10.1002/hep.21902] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
510 Quintela BM, Conway JM, Hyman JM, Guedj J, Dos Santos RW, Lobosco M, Perelson AS. A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents. Front Microbiol 2018;9:601. [PMID: 29670586 DOI: 10.3389/fmicb.2018.00601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
511 Shimakami T, Lanford RE, Lemon SM. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr Opin Pharmacol 2009;9:537-44. [PMID: 19762279 DOI: 10.1016/j.coph.2009.08.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
512 Di Pucchio T, Chatterjee B, Smed-Sörensen A, Clayton S, Palazzo A, Montes M, Xue Y, Mellman I, Banchereau J, Connolly JE. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008;9:551-7. [PMID: 18376401 DOI: 10.1038/ni.1602] [Cited by in Crossref: 198] [Cited by in F6Publishing: 201] [Article Influence: 15.2] [Reference Citation Analysis]
513 Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703-714. [PMID: 14988824 DOI: 10.1053/j.gastro.2003.12.002] [Cited by in Crossref: 186] [Cited by in F6Publishing: 153] [Article Influence: 10.9] [Reference Citation Analysis]
514 Blum HE, Moradpour D. Viral pathogenesis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17 Suppl 3:S413-S420. [PMID: 12472973 DOI: 10.1046/j.1440-1746.17.s3.37.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
515 Cardozo EF, Ji D, Lau G, Schinazi RF, Chen GF, Ribeiro RM, Perelson AS. Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy. J Viral Hepat 2020;27:261-9. [PMID: 31670859 DOI: 10.1111/jvh.13229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
516 He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, Nolan GP, Pfeffer LM, Wright TL, Risch N. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology. 2006;44:352-359. [PMID: 16871572 DOI: 10.1002/hep.21267] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 4.9] [Reference Citation Analysis]
517 Haseltine EL, Kimko H, Luo H, Tolsma J, Bartels DJ, Kieffer TL, Garg V. Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. J Pharmacokinet Pharmacodyn 2015;42:681-98. [PMID: 26289844 DOI: 10.1007/s10928-015-9435-z] [Reference Citation Analysis]
518 Salvatierra K, Fareleski S, Forcada A, López-Labrador FX. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World J Virol. 2013;2:6-15. [PMID: 24175225 DOI: 10.5501/wjv.v2.i1.6] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
519 Easter JA, Burrell RC, Bonacorsi SJ Jr. Synthesis of isotopically labeled daclatasvir for use in human clinical studies. J Labelled Comp Radiopharm 2016;59:164-70. [PMID: 26968868 DOI: 10.1002/jlcr.3386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
520 Pinky L, González-Parra G, Dobrovolny HM. Superinfection and cell regeneration can lead to chronic viral coinfections. J Theor Biol 2019;466:24-38. [PMID: 30639572 DOI: 10.1016/j.jtbi.2019.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
521 von Wagner M, Lee JH, Rüster B, Kronenberger B, Sarrazin C, Roth WK, Zeuzem S. Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment. J Viral Hepat 2003;10:413-22. [PMID: 14633173 DOI: 10.1046/j.1365-2893.2003.00457.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
522 Shaker OG, Sadik NA, El-dessouki A. Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide −443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C. Human Immunology 2012;73:1039-45. [DOI: 10.1016/j.humimm.2012.07.329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
523 Izumi N, Kumada H, Hashimoto N, Harada H, Imawari M, Zeniya M, Toda G. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Dig Dis Sci 2001;46:516-23. [PMID: 11318525 DOI: 10.1023/a:1005686829416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
524 Wu H. Statistical methods for HIV dynamic studies in AIDS clinical trials. Stat Methods Med Res 2005;14:171-92. [PMID: 15807150 DOI: 10.1191/0962280205sm390oa] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
525 Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, García-Sandoval M, Soto L, Rodríguez R, Gutiérrez-Ruíz MC, Gutiérrez-Reyes G, Bonder A, Olivera MA, Kershenobich D. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin. Liver Int 2005;25:91-5. [PMID: 15698404 DOI: 10.1111/j.1478-3231.2005.1040.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
526 Balagopal A, Smeaton LM, Quinn J, Venuto CS, Morse GD, Vu V, Alston-Smith B, Cohen DE, Santana-Bagur JL, Anthony DD, Sulkowski MS, Wyles DL, Talal AH. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. J Infect Dis 2020;222:601-10. [PMID: 32201883 DOI: 10.1093/infdis/jiaa126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
527 Cheng PN, Marcellin P, Bacon B, Farrell G, Parsons I, Wee T, Chang TT. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J Viral Hepat. 2004;11:418-426. [PMID: 15357646 DOI: 10.1111/j.1365-2893.2004.00514.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
528 Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. J Virol 2021;95:e0049220. [PMID: 33910953 DOI: 10.1128/JVI.00492-20] [Reference Citation Analysis]
529 Tran T, Pryde DC, Jones P, Adam FM, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Gardner I, Jones HM, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection. Bioorganic & Medicinal Chemistry Letters 2011;21:2389-93. [DOI: 10.1016/j.bmcl.2011.02.092] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
530 Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ogawa E, Toyoda K, Taniai H, Kainuma M, Murata M, Hayashi J. Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Journal of Infection and Chemotherapy 2011;17:737-43. [DOI: 10.1007/s10156-011-0249-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
531 Das S, Shetty RK, Kumar A, Shridharan RN, Tatineni R, Chi G, Mukherjee A, Das S, Subbarao SM, Karande AA. Monoclonal antibodies against Hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system. PLoS One 2013;8:e53619. [PMID: 23341957 DOI: 10.1371/journal.pone.0053619] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
532 Gregori J, Esteban JI, Cubero M, Garcia-Cehic D, Perales C, Casillas R, Alvarez-Tejado M, Rodríguez-Frías F, Guardia J, Domingo E, Quer J. Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants. PLoS One 2013;8:e83361. [PMID: 24391758 DOI: 10.1371/journal.pone.0083361] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
533 Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 2008;3:e2660. [PMID: 18628977 DOI: 10.1371/journal.pone.0002660] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
534 Fourati S, Pawlotsky JM. Virologic Tools for HCV Drug Resistance Testing. Viruses 2015;7:6346-59. [PMID: 26690198 DOI: 10.3390/v7122941] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
535 Pawlotsky J, Mchutchison JG. Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 2004;39:554-67. [DOI: 10.1002/hep.20065] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
536 Ahmed A, Keeffe EB. OVERVIEW OF INTERFERON THERAPY FOR CHRONIC HEPATITIS C. Clinics in Liver Disease 1999;3:757-73. [DOI: 10.1016/s1089-3261(05)70237-3] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
537 Hill AL. Mathematical Models of HIV Latency. Curr Top Microbiol Immunol 2018;417:131-56. [PMID: 29164341 DOI: 10.1007/82_2017_77] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
538 Gale M Jr, Tan SL, Katze MG. Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev 2000;64:239-80. [PMID: 10839817 DOI: 10.1128/MMBR.64.2.239-280.2000] [Cited by in Crossref: 235] [Cited by in F6Publishing: 138] [Article Influence: 11.2] [Reference Citation Analysis]
539 Shobokshi OA, Serebour FE, Skakni L. Chronic Hepatitis C Treatment: A Review. Ann Saudi Med 2000;20:402-8. [DOI: 10.5144/0256-4947.2000.402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
540 Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology 2005;128:1056-66. [DOI: 10.1053/j.gastro.2005.01.049] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
541 Peck KM, Chan CH, Tanaka MM. Connecting within-host dynamics to the rate of viral molecular evolution. Virus Evol 2015;1:vev013. [PMID: 27774285 DOI: 10.1093/ve/vev013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
542 Berger KL, Lagacé L, Triki I, Cartier M, Marquis M, Lawetz C, Bethell R, Scherer J, Kukolj G. Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study. Antimicrob Agents Chemother 2013;57:4928-36. [PMID: 23877706 DOI: 10.1128/AAC.00822-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
543 Hattaf K, Yousfi N. A generalized HBV model with diffusion and two delays. Computers & Mathematics with Applications 2015;69:31-40. [DOI: 10.1016/j.camwa.2014.11.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
544 Cappuccio A, Tieri P, Castiglione F. Multiscale modelling in immunology: a review. Brief Bioinform 2016;17:408-18. [PMID: 25810307 DOI: 10.1093/bib/bbv012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
545 Quinn TC. Viral kinetics of genital herpes: a molecular probe into host-viral interactions. J Infect Dis 2011;204:495-8. [PMID: 21791649 DOI: 10.1093/infdis/jir317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
546 Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, Conrad AJ, McHutchison J, Perelson AS. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl. 2006;12:207-216. [PMID: 16447184 DOI: 10.1002/lt.20572] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
547 Lejnine S, Marton MJ, Wang IM, Howell BJ, Webber AL, Maxwell JW, Shire N, Malkov V, Lunceford J, Zeremski M, Sun A, Ruddy M, Talal AH. Gene expression analysis in serial liver fine needle aspirates. J Viral Hepat 2015;22:64-76. [PMID: 24475909 DOI: 10.1111/jvh.12213] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
548 Aston PJ. A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis and Implications. Viruses 2018;10:E195. [PMID: 29652855 DOI: 10.3390/v10040195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
549 Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47:35-42. [PMID: 17975791 DOI: 10.1002/hep.21975] [Cited by in Crossref: 157] [Cited by in F6Publishing: 128] [Article Influence: 12.1] [Reference Citation Analysis]
550 Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002;123:1070-1083. [PMID: 12360469 DOI: 10.1053/gast.2002.36045] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 7.3] [Reference Citation Analysis]
551 Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, Bigger CB. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006;43:961-72. [PMID: 16628626 DOI: 10.1002/hep.21167] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
552 Colombatto P, Ciccorossi P, Maina AM, Civitano L, Oliveri F, Coco B, Romagnoli V, Bonino F, Brunetto MR. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther 2008;84:212-5. [PMID: 18388885 DOI: 10.1038/clpt.2008.21] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
553 Paulon E, Naoumov NV. Individualization of antiviral treatment regimens for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:321-5. [PMID: 16538101 DOI: 10.1097/00042737-200604000-00003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
554 Upton RN, Mould DR. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst Pharmacol 2014;3:e88. [PMID: 24384783 DOI: 10.1038/psp.2013.71] [Cited by in Crossref: 119] [Cited by in F6Publishing: 96] [Article Influence: 17.0] [Reference Citation Analysis]
555 Karino Y, Toyota J, Sugawara M, Miyazaki K, Kuwata Y, Yamazaki K, Sato T, Ohmura T, Matsushima T. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003;18:404-10. [PMID: 12653888 DOI: 10.1046/j.1440-1746.2003.03009.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
556 Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CA. Assessing mathematical models of influenza infections using features of the immune response. PLoS One 2013;8:e57088. [PMID: 23468916 DOI: 10.1371/journal.pone.0057088] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
557 Hoofnagle JH. Management of hepatitis C: current and future perspectives. J Hepatol 1999;31 Suppl 1:264-8. [PMID: 10622600 DOI: 10.1016/s0168-8278(99)80414-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
558 González-Peralta RP, Galasso GJ, Poynard T, Schalm S, Thomas HC, Wright TL. Summary of the first international symposium on viral hepatitis. Antiviral Res 1999;42:77-96. [PMID: 10389652 DOI: 10.1016/s0166-3542(99)00023-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
559 Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003;37:610-621. [PMID: 12601359 DOI: 10.1053/jhep.2003.50105] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 4.7] [Reference Citation Analysis]
560 Weiland O. Treatment of naive patients with chronic hepatitis C. J Hepatol 1999;31 Suppl 1:168-73. [PMID: 10622581 DOI: 10.1016/s0168-8278(99)80395-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
561 Cotler SJ, Jensen DM. TREATMENT OF HEPATITIS C VIRUS AND HIV CO-INFECTIONS. Clinics in Liver Disease 2001;5:1045-61. [DOI: 10.1016/s1089-3261(05)70208-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
562 Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol. 2009;83:6149-6160. [PMID: 19321602 DOI: 10.1128/jvi.00248-09] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
563 To J, Surya W, Torres J. Targeting the Channel Activity of Viroporins. Adv Protein Chem Struct Biol 2016;104:307-55. [PMID: 27038378 DOI: 10.1016/bs.apcsb.2015.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
564 Gupta S, Singh R. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS One 2012;7:e41209. [PMID: 22911761 DOI: 10.1371/journal.pone.0041209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
565 Murray JM, Ribeiro RM. Special Issue "Mathematical Modeling of Viral Infections". Viruses 2018;10:E303. [PMID: 29866993 DOI: 10.3390/v10060303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
566 Guedj J, Dahari H, Perelson AS. Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy. Proc Natl Acad Sci U S A 2011;108:E302; author reply E303. [PMID: 21719708 DOI: 10.1073/pnas.1104149108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
567 Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep 2008;7:97-105. [PMID: 19148305 DOI: 10.1007/s11901-008-0022-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
568 Kaser A, Enrich B, Ludwiczek O, Vogel W, Tilg H. Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin Exp Immunol 1999;118:71-7. [PMID: 10540162 DOI: 10.1046/j.1365-2249.1999.01020.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
569 Hawkins J, Molinek D. Markov cellular automata models for chronic disease progression. Int J Biomath 2015;08:1550085. [DOI: 10.1142/s1793524515500850] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
570 Hong Z. Ribavirin mutagenesis: Hidden clues in mathematical models. Hepatology 2005;41:1399-402. [DOI: 10.1002/hep.20730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
571 Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010;51:1523-1530. [PMID: 20186843 DOI: 10.1002/hep.23509] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 8.3] [Reference Citation Analysis]
572 Gaeta GB, Stornaiuolo G, Stanzione M, Ascione T, Pasquazzi C, Taliani G, Cimino L, Budillon G, Piccinino F. Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. J Viral Hepat 2001;8:284-6. [DOI: 10.1046/j.1365-2893.2001.00298.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
573 Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 2011;25:2197-208. [PMID: 21866039 DOI: 10.1097/QAD.0b013e32834bbb90] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
574 Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002;35:224-31. [PMID: 11786980 DOI: 10.1053/jhep.2002.30531] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 6.2] [Reference Citation Analysis]
575 Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol. 1999;31 Suppl 1:71-79. [PMID: 10622564 DOI: 10.1016/s0168-8278(99)80378-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
576 Gibbert K, Joedicke JJ, Meryk A, Trilling M, Francois S, Duppach J, Kraft A, Lang KS, Dittmer U. Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog. 2012;8:e1002868. [PMID: 22912583 DOI: 10.1371/journal.ppat.1002868] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
577 Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 2006;66:1807-15. [PMID: 17040112 DOI: 10.2165/00003495-200666140-00003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
578 Davis GL. New schedules of interferon for chronic hepatitis C. J Hepatol. 1999;31 Suppl 1:227-231. [PMID: 10622593 DOI: 10.1016/s0168-8278(99)80407-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
579 Youn JW, Park SH, Cho JH, Sung YC. Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. J Virol. 2003;77:11596-11602. [PMID: 14557645 DOI: 10.1128/jvi.77.21.11596-11602.2003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
580 Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol 2011;7:e1001072. [PMID: 21304937 DOI: 10.1371/journal.pcbi.1001072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
581 Myrmel H, Ulvestad E, Asjø B. The hepatitis C virus enigma. APMIS 2009;117:427-39. [PMID: 19400866 DOI: 10.1111/j.1600-0463.2009.02454.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
582 Chen SC, Chio CP, Jou LJ, Liao CM. Viral kinetics and exhaled droplet size affect indoor transmission dynamics of influenza infection. Indoor Air 2009;19:401-13. [DOI: 10.1111/j.1600-0668.2009.00603.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
583 Horner SM, Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res. 2009;29:489-498. [PMID: 19708811 DOI: 10.1089/jir.2009.0063] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
584 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2007;3:469-76. [PMID: 24395487 DOI: 10.1007/s11908-007-1004-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
585 Regev A, Schiff ER. Viral hepatitis. Curr Opin Gastroenterol 1999;15:234-9. [PMID: 17023950 DOI: 10.1097/00001574-199905000-00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
586 Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin Investig Drugs 2009;18:709-25. [PMID: 19426125 DOI: 10.1517/13543780902854194] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
587 Kalemera M, Mincheva D, Grove J, Illingworth CJR. Building a mechanistic mathematical model of hepatitis C virus entry. PLoS Comput Biol 2019;15:e1006905. [PMID: 30883541 DOI: 10.1371/journal.pcbi.1006905] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
588 Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomedicine & Pharmacotherapy 2011;65:303-6. [DOI: 10.1016/j.biopha.2011.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
589 Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis. 2003;16:587-592. [PMID: 14624110 DOI: 10.1097/00001432-200312000-00012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
590 Campo DS, Skums P, Dimitrova Z, Vaughan G, Forbi JC, Teo CG, Khudyakov Y, Lau DT. Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy. Clin Pharmacol Ther 2014;95:627-35. [PMID: 24488144 DOI: 10.1038/clpt.2014.20] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
591 Chen SC, You SH, Liu CY, Chio CP, Liao CM. Using experimental human influenza infections to validate a viral dynamic model and the implications for prediction. Epidemiol Infect 2012;140:1557-68. [PMID: 22078059 DOI: 10.1017/S0950268811002226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
592 Wright M, Main J, Thomas HC. Treatment of chronic viral hepatitis. Antivir Chem Chemother 2001;12:201-12. [PMID: 11771729 DOI: 10.1177/095632020101200401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
593 Waheed Y, Bhatti A, Ashraf M. RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs. Infection, Genetics and Evolution 2013;14:247-57. [DOI: 10.1016/j.meegid.2012.12.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
594 Dahari H, Ribeiro RM, Rice CM, Perelson AS. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 2007;81:750-60. [PMID: 17035310 DOI: 10.1128/JVI.01304-06] [Cited by in Crossref: 79] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
595 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha. J Med Virol 2009;81:1354-62. [DOI: 10.1002/jmv.21533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
596 Balagopal A, Kandathil AJ, Higgins YH, Wood J, Richer J, Quinn J, Eldred L, Li Z, Ray SC, Sulkowski MS, Thomas DL. Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patient. Hepatology. 2014;60:477-486. [PMID: 24706559 DOI: 10.1002/hep.27158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
597 Hattaf K, Yousfi N, Tridane A. Stability analysis of a virus dynamics model with general incidence rate and two delays. Applied Mathematics and Computation 2013;221:514-21. [DOI: 10.1016/j.amc.2013.07.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
598 Gilchrist MA, Coombs D, Perelson AS. Optimizing within-host viral fitness: infected cell lifespan and virion production rate. Journal of Theoretical Biology 2004;229:281-8. [DOI: 10.1016/j.jtbi.2004.04.015] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
599 Karnam US, Reddy KR. Pegylated interferons. Clin Liver Dis 2003;7:139-48. [PMID: 12691463 DOI: 10.1016/s1089-3261(02)00072-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
600 Maggi F, Focosi D, Albani M, Lanini L, Vatteroni ML, Petrini M, Ceccherini-Nelli L, Pistello M, Bendinelli M. Role of hematopoietic cells in the maintenance of chronic human torquetenovirus plasma viremia. J Virol. 2010;84:6891-6893. [PMID: 20410268 DOI: 10.1128/jvi.00273-10] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
601 Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-1358. [PMID: 12774014 DOI: 10.1053/jhep.2003.50218] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 10.1] [Reference Citation Analysis]
602 Scholtes C, André P, Trépo C, Cornu C, Remontet L, Ecochard R, Bejan-Angoulvant T, Gueyffier F. Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial. Therapie 2012;67:423-7. [PMID: 23241251 DOI: 10.2515/therapie/2012058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
603 Nubling CM, Unger G, Chudy M, Raia S, Lower J. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002;42:1037-45. [DOI: 10.1046/j.1537-2995.2002.00166.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 3.7] [Reference Citation Analysis]
604 Shudo E, Ribeiro RM, Perelson AS. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat 2008;15:379-82. [PMID: 18266841 DOI: 10.1111/j.1365-2893.2008.00977.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
605 Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 2012;8:e1002881. [PMID: 22927817 DOI: 10.1371/journal.ppat.1002881] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 12.8] [Reference Citation Analysis]
606 Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004;114:250-259. [PMID: 15254592 DOI: 10.1172/jci200420985] [Cited by in Crossref: 109] [Article Influence: 6.4] [Reference Citation Analysis]
607 Khu YL, Tan YJ, Lim SG, Hong W, Goh PY. Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochem J. 2004;384:401-409. [PMID: 15303969 DOI: 10.1042/bj20040858] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
608 Lopez Angel CJ, Pham EA, Du H, Vallania F, Fram BJ, Perez K, Nguyen T, Rosenberg-Hasson Y, Ahmed A, Dekker CL, Grant PM, Khatri P, Maecker HT, Glenn JS, Davis MM, Furman D. Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proc Natl Acad Sci U S A 2021;118:e2022928118. [PMID: 33811141 DOI: 10.1073/pnas.2022928118] [Reference Citation Analysis]
609 Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009;7:249-253. [PMID: 19344238 DOI: 10.1586/eri.09.5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
610 Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17-27. [PMID: 16501853 DOI: 10.1007/s00535-005-1740-7] [Cited by in Crossref: 112] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
611 Wolters LM, Hansen BE, Niesters HG, Dehertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. Journal of Hepatology 2002;37:137-44. [DOI: 10.1016/s0168-8278(02)00115-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
612 Brenndörfer ED, Sällberg M. Hepatitis C virus-mediated modulation of cellular immunity. Arch Immunol Ther Exp (Warsz) 2012;60:315-29. [PMID: 22911132 DOI: 10.1007/s00005-012-0184-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
613 Chatterjee A, Guedj J, Perelson AS. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther. 2012;17:1171-1182. [PMID: 23186606 DOI: 10.3851/imp2428] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
614 Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181-191. [PMID: 24911972 DOI: 10.1016/j.antiviral.2014.05.015] [Cited by in Crossref: 149] [Cited by in F6Publishing: 136] [Article Influence: 21.3] [Reference Citation Analysis]
615 Coombs D, Gilchrist MA, Ball CL. Evaluating the importance of within- and between-host selection pressures on the evolution of chronic pathogens. Theoretical Population Biology 2007;72:576-91. [DOI: 10.1016/j.tpb.2007.08.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 72] [Article Influence: 6.6] [Reference Citation Analysis]
616 Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol. 2003;13:57-68. [PMID: 12516062 DOI: 10.1002/rmv.371] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 4.6] [Reference Citation Analysis]
617 Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem. 2012;55:2481-2531. [PMID: 22185586 DOI: 10.1021/jm201384j] [Cited by in Crossref: 197] [Cited by in F6Publishing: 165] [Article Influence: 21.9] [Reference Citation Analysis]
618 Layden-almer JE, Cotler SJ, Layden TJ. Viral kinetics in the treatment of chronic hepatitis C. J Viral Hepat 2006;13:499-504. [DOI: 10.1111/j.1365-2893.2006.00715.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
619 Meuleman TJ, Cowton VM, Patel AH, Liskamp RMJ. Design and Synthesis of HCV-E2 Glycoprotein Epitope Mimics in Molecular Construction of Potential Synthetic Vaccines. Viruses 2021;13:326. [PMID: 33672697 DOI: 10.3390/v13020326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 2009;53:926-34. [PMID: 19075052 DOI: 10.1128/AAC.01032-08] [Cited by in Crossref: 69] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
621 Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med 2015;5:a021543. [PMID: 26253093 DOI: 10.1101/cshperspect.a021543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
622 Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, Ffrench RA. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007;85:24-32. [PMID: 17130897 DOI: 10.1038/sj.icb.7100010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
623 Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005;106:1175-82. [PMID: 15860662 DOI: 10.1182/blood-2005-01-0126] [Cited by in Crossref: 130] [Cited by in F6Publishing: 122] [Article Influence: 8.1] [Reference Citation Analysis]
624 Padmanabhan P, Garaigorta U, Dixit NM. Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment. Nat Commun 2014;5:3872. [PMID: 24834957 DOI: 10.1038/ncomms4872] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
625 Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822-832. [PMID: 20564352 DOI: 10.1002/hep.23743] [Cited by in Crossref: 175] [Cited by in F6Publishing: 163] [Article Influence: 15.9] [Reference Citation Analysis]
626 Desikan R, Antia R, Dixit NM. Physical 'strength' of the multi-protein chain connecting immune cells: Does the weakest link limit antibody affinity maturation?: The weakest link in the multi-protein chain facilitating antigen acquisition by B cells in germinal centres limits antibody affinity maturation. Bioessays 2021;43:e2000159. [PMID: 33448042 DOI: 10.1002/bies.202000159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One 2017;12:e0177352. [PMID: 28545127 DOI: 10.1371/journal.pone.0177352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
628 Bennett F, Huang Y, Hendrata S, Lovey R, Bogen SL, Pan W, Guo Z, Prongay A, Chen KX, Arasappan A, Venkatraman S, Velazquez F, Nair L, Sannigrahi M, Tong X, Pichardo J, Cheng KC, Girijavallabhan VM, Saksena AK, Njoroge FG. The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor. Bioorg Med Chem Lett 2010;20:2617-21. [PMID: 20303756 DOI: 10.1016/j.bmcl.2010.02.063] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
629 Callendret B, Bukh J, Eccleston HB, Heksch R, Hasselschwert DL, Purcell RH, Hughes AL, Walker CM. Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8⁺ T cells in early viral evolution. J Virol 2011;85:11833-45. [PMID: 21900166 DOI: 10.1128/JVI.02654-10] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
630 Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264; quiz 214-217. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 236] [Article Influence: 17.4] [Reference Citation Analysis]
631 Titze MI, Frank J, Ehrhardt M, Smola S, Graf N, Lehr T. A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth. Eur J Pharm Sci 2017;97:38-46. [PMID: 27825920 DOI: 10.1016/j.ejps.2016.11.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
632 Arnaout RA, Nowak MA, Wodarz D. HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc Biol Sci 2000;267:1347-54. [PMID: 10972131 DOI: 10.1098/rspb.2000.1149] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
633 Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Dig Liver Dis 2015;47:157-63. [PMID: 25544656 DOI: 10.1016/j.dld.2014.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
634 Thibeault D, Bousquet C, Gingras R, Lagacé L, Maurice R, White PW, Lamarre D. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 2004;78:7352-9. [PMID: 15220408 DOI: 10.1128/JVI.78.14.7352-7359.2004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
635 Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology. 2008;370:237-245. [PMID: 18006035 DOI: 10.1016/j.virol.2007.10.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
636 Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, Smith J, McClure MO, Karayiannis P. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60:837-845. [PMID: 21139063 DOI: 10.1136/gut.2010.217166] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 10.9] [Reference Citation Analysis]
637 Bassit L, Grier J, Bennett M, Schinazi RF. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother 2008;19:25-31. [PMID: 18610555 DOI: 10.1177/095632020801900104] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
638 Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol. 2011;85:10451-10463. [PMID: 21813602 DOI: 10.1128/jvi.05259-11] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
639 Dahari H, Cotler SJ, Layden TJ, Perelson AS. Hepatitis B virus clearance rate estimates. Hepatology 2009;49:1779-80; author reply 1780-1. [PMID: 19402118 DOI: 10.1002/hep.22874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
640 Canini L, Chatterjee A, Guedj J, Lemenuel-Diot A, Brennan B, Smith PF, Perelson AS. A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antivir Ther 2015;20:469-77. [PMID: 25321394 DOI: 10.3851/IMP2879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
641 Wang HC, Ren YP, Qiu Y, Zheng J, Li GL, Hu CP, Zhou TY, Lu W, Li L. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 2018;39:140-53. [PMID: 28880015 DOI: 10.1038/aps.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
642 Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol 2009;2:205-19. [PMID: 21180544 DOI: 10.1177/1756283X09336045] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
643 Senturk H, Ersoz G, Ozaras R, Kaymakoglu S, Bozkaya H, Akdogan M, Mert A, Bozdayi M, Tabak F, Yenice N, Ozbay G. Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial. Dig Dis Sci 2003;48:1124-9. [PMID: 12822874 DOI: 10.1023/a:1023725014751] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
644 Cabot B, Martell M, Esteban JI, Piron M, Otero T, Esteban R, Guardia J, Gómez J. Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients. J Virol 2001;75:12005-13. [PMID: 11711591 DOI: 10.1128/JVI.75.24.12005-12013.2001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
645 Irausquin SJ, Hughes AL. Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b. Virus Res 2010;147:202-7. [PMID: 19896990 DOI: 10.1016/j.virusres.2009.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
646 Conway JM, Perelson AS. A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis. PLoS Comput Biol 2014;10:e1003769. [PMID: 25101902 DOI: 10.1371/journal.pcbi.1003769] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
647 Morishima C, Gretch DR. CLINICAL USE OF HEPATITIS C VIRUS TESTS FOR DIAGNOSIS AND MONITORING DURING THERAPY. Clinics in Liver Disease 1999;3:717-40. [DOI: 10.1016/s1089-3261(05)70235-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
648 Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005;79:11095-104. [PMID: 16103160 DOI: 10.1128/JVI.79.17.11095-11104.2005] [Cited by in Crossref: 212] [Cited by in F6Publishing: 145] [Article Influence: 13.3] [Reference Citation Analysis]
649 Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011;29:993-1003. [PMID: 22068541 DOI: 10.1038/nbt.2020] [Cited by in Crossref: 203] [Cited by in F6Publishing: 162] [Article Influence: 20.3] [Reference Citation Analysis]
650 Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, Jacobson-Brown P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem. 2001;34:173-182. [PMID: 11408014 DOI: 10.1016/s0009-9120(01)00212-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
651 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 413] [Article Influence: 30.3] [Reference Citation Analysis]
652 Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol. 2008;317:1-38. [PMID: 17990788 DOI: 10.1007/978-3-540-72146-8_1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
653 Wang T, Blatt LM, Seiwert SD. Immunomodulatory Activities of IFN-γ1b in Combination with Type I IFN: Implications for the Use of IFN-γ1b in the Treatment of Chronic HCV Infections. Journal of Interferon & Cytokine Research 2006;26:473-83. [DOI: 10.1089/jir.2006.26.473] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
654 [DOI: 10.1063/1.5127485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
655 Li H, McMahon BJ, McArdle S, Bruden D, Sullivan DG, Shelton D, Deubner H, Gretch DR. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 2008;375:580-91. [PMID: 18343477 DOI: 10.1016/j.virol.2008.02.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
656 Hamza A, Ahmad I, Uneeb M. Fuzzy logic and Lyapunov-based non-linear controllers for HCV infection. IET Syst Biol 2021;15:53-71. [PMID: 33780147 DOI: 10.1049/syb2.12014] [Reference Citation Analysis]
657 Li H, Stoddard MB, Wang S, Giorgi EE, Blair LM, Learn GH, Hahn BH, Alter HJ, Busch MP, Fierer DS, Ribeiro RM, Perelson AS, Bhattacharya T, Shaw GM. Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol 2016;90:152-66. [PMID: 26468546 DOI: 10.1128/JVI.02156-15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
658 Thézé J, Lowes S, Parker J, Pybus OG. Evolutionary and Phylogenetic Analysis of the Hepaciviruses and Pegiviruses. Genome Biol Evol 2015;7:2996-3008. [PMID: 26494702 DOI: 10.1093/gbe/evv202] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
659 Prabhu RA, Goyal NK, Nair NS, Pai G, Wadhwa T, Prabhu RA. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd007003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
660 Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005;43:186-91. [PMID: 15634970 DOI: 10.1128/JCM.43.1.186-191.2005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
661 Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ, Chang MH, Chen DS. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol. 2010;84:3454-3463. [PMID: 20089644 DOI: 10.1128/jvi.02164-09] [Cited by in Crossref: 68] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
662 Ho CKY, Welkers MRA, Thomas XV, Sullivan JC, Kieffer TL, Reesink HW, Rebers SPH, de Jong MD, Schinkel J, Molenkamp R. A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants. J Virol Methods 2015;219:28-37. [PMID: 25818622 DOI: 10.1016/j.jviromet.2015.03.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
663 Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999;73:2938-46. [PMID: 10074143 DOI: 10.1128/JVI.73.4.2938-2946.1999] [Cited by in Crossref: 142] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
664 Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, Kovelsky R, Ni ZJ, Zhu Q, Hashash A. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology. 2006;43:1346-1353. [PMID: 16729319 DOI: 10.1002/hep.21209] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 5.2] [Reference Citation Analysis]
665 Brunetto MR, Colombatto P, Bonino F. Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. World J Gastroenterol 2009;15:531-7. [PMID: 19195054 DOI: 10.3748/wjg.15.531] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
666 Bartenschlager R. The hepatitis C virus replicon system: from basic research to clinical application. J Hepatol 2005;43:210-6. [PMID: 15964655 DOI: 10.1016/j.jhep.2005.05.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
667 Castelain S, Descamps V, Thibault V, Francois C, Bonte D, Morel V, Izopet J, Capron D, Zawadzki P, Duverlie G. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol. 2004;31:227-234. [PMID: 15465417 DOI: 10.1016/j.jcv.2004.03.009] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
668 Enomoto S, Tamai H, Oka M, Shingaki N, Shiraki T, Takeuchi M, Deguchi H, Magari H, Inoue I, Iguchi M, Yanaoka K, Arii K, Fujishiro M, Yahagi N, Yotsuyanagi H, Ichinose M. Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level. Hepatology Research 2007;37:692-700. [DOI: 10.1111/j.1872-034x.2007.00112.x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
669 Rosenberg P. Hepatitis C: A Hepatologist's Approach to an Infectious Disease. CLIN INFECT DIS 2001;33:1728-32. [DOI: 10.1086/323128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
670 Major ME. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses 2009;1:144-65. [PMID: 21994543 DOI: 10.3390/v1020144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
671 Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Crönlein J, Chaves RL, Yong C, Nehmiz G, Steinmann GG. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-55. [DOI: 10.1053/j.gastro.2004.08.002] [Cited by in Crossref: 243] [Cited by in F6Publishing: 201] [Article Influence: 14.3] [Reference Citation Analysis]
672 Wodarz D. Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses. J Gen Virol. 2003;84:1743-1750. [PMID: 12810868 DOI: 10.1099/vir.0.19118-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
673 Perelso